ArrayFilename	!Sample_title	!Sample_geo_accession	SLEDAI	!Sample_status	!Sample_submission_date	!Sample_last_update_date	!Sample_characteristics_ch1	!Sample_type	!Sample_channel_count	!Sample_source_name_ch1	!Sample_organism_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_treatment_protocol_ch1	!Sample_molecule_ch1	!Sample_extract_protocol_ch1	!Sample_label_ch1	!Sample_label_protocol_ch1	!Sample_taxid_ch1	!Sample_hyb_protocol	!Sample_scan_protocol	!Sample_description	!Sample_data_processing	!Sample_platform_id	!Sample_contact_name	!Sample_contact_email	!Sample_contact_phone	!Sample_contact_department	!Sample_contact_institute	!Sample_contact_address	!Sample_contact_city	!Sample_contact_state	!Sample_contact_zip/postal_code	!Sample_contact_country	!Sample_supplementary_file	!Sample_data_row_count	!Sample_relation	!series_matrix_table_begin	ID_REF	!series_matrix_table_endGSM2352693_A52084400940546091515421247226883.CEL	"SUBJ.1720, SLE, baseline"	GSM2352693	sledai_at_baseline: 4	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6438356164383	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1720	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 99	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352693/suppl/GSM2352693_A52084400940546091515421247226883.CEL.gz	0	Reanalyzed by: GSM2351364		GSM2352693	GSM2352694_A52084400939920091515421247126513.CEL	"SUBJ.1720, SLE, week16"	GSM2352694	sledai_at_baseline: 4	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6438356164383	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1720	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 99	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352694/suppl/GSM2352694_A52084400939920091515421247126513.CEL.gz	0			GSM2352694	GSM2352695_A52084400940545091515421247226837.CEL	"SUBJ.1720, SLE, week52"	GSM2352695	sledai_at_baseline: 4	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6438356164383	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1720	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 99	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352695/suppl/GSM2352695_A52084400940545091515421247226837.CEL.gz	0			GSM2352695	GSM2352696_A52084400939234091415421177246952.CEL	"SUBJ.0003, SLE, baseline"	GSM2352696	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.3534246575342	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0003	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.28	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352696/suppl/GSM2352696_A52084400939234091415421177246952.CEL.gz	0	Reanalyzed by: GSM2351859		GSM2352696	GSM2352697_A52084400939472101415421438760275.CEL	"SUBJ.0003, SLE, week16"	GSM2352697	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.3534246575342	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0003	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.28	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352697/suppl/GSM2352697_A52084400939472101415421438760275.CEL.gz	0			GSM2352697	GSM2352698_A52084400939472101415421438760278.CEL	"SUBJ.0003, SLE, week52"	GSM2352698	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.3534246575342	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0003	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.28	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352698/suppl/GSM2352698_A52084400939472101415421438760278.CEL.gz	0			GSM2352698	GSM2352699_A52084400939852091415421246947127.CEL	"SUBJ.0065, SLE, baseline"	GSM2352699	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.7185792349726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0065	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.897	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352699/suppl/GSM2352699_A52084400939852091415421246947127.CEL.gz	0	Reanalyzed by: GSM2351291		GSM2352699	GSM2352700_A52084400939854091415421246947243.CEL	"SUBJ.0065, SLE, week52"	GSM2352700	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.7185792349726	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0065	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.897	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352700/suppl/GSM2352700_A52084400939854091415421246947243.CEL.gz	0			GSM2352700	GSM2352701_A52084400939234091415421177246956.CEL	"SUBJ.1587, SLE, baseline"	GSM2352701	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8438356164383	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1587	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 104	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352701/suppl/GSM2352701_A52084400939234091415421177246956.CEL.gz	0	Reanalyzed by: GSM2351616		GSM2352701	GSM2352702_A52084400939233091415421177246881.CEL	"SUBJ.1587, SLE, week16"	GSM2352702	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8438356164383	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1587	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 104	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352702/suppl/GSM2352702_A52084400939233091415421177246881.CEL.gz	0			GSM2352702	GSM2352703_A52084400939235091415421177247076.CEL	"SUBJ.1587, SLE, week52"	GSM2352703	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8438356164383	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1587	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 104	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352703/suppl/GSM2352703_A52084400939235091415421177247076.CEL.gz	0			GSM2352703	GSM2352704_A52084400939843091415421247047451.CEL	"SUBJ.1028, SLE, baseline"	GSM2352704	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8551912568306	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1028	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352704/suppl/GSM2352704_A52084400939843091415421247047451.CEL.gz	0	Reanalyzed by: GSM2352308		GSM2352704	GSM2352705_A52084400939232091415421177246853.CEL	"SUBJ.1028, SLE, week16"	GSM2352705	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8551912568306	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1028	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352705/suppl/GSM2352705_A52084400939232091415421177246853.CEL.gz	0			GSM2352705	GSM2352706_A52084400939232091415421177246844.CEL	"SUBJ.1028, SLE, week52"	GSM2352706	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8551912568306	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1028	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352706/suppl/GSM2352706_A52084400939232091415421177246844.CEL.gz	0			GSM2352706	GSM2352707_A52084400939847091515421247126705.CEL	"SUBJ.0901, SLE, baseline"	GSM2352707	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.7978142076502	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0901	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352707/suppl/GSM2352707_A52084400939847091515421247126705.CEL.gz	0	Reanalyzed by: GSM2351303		GSM2352707	GSM2352708_A52084400939847091515421247126706.CEL	"SUBJ.0901, SLE, week16"	GSM2352708	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.7978142076502	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0901	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352708/suppl/GSM2352708_A52084400939847091515421247126706.CEL.gz	0			GSM2352708	GSM2352709_A52084400940546091515421247226885.CEL	"SUBJ.0901, SLE, week52"	GSM2352709	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.7978142076502	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0901	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352709/suppl/GSM2352709_A52084400940546091515421247226885.CEL.gz	0			GSM2352709	GSM2352710_A52084400940658100115421372840918.CEL	"SUBJ.1544, SLE, baseline"	GSM2352710	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.811475409836	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1544	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.059	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352710/suppl/GSM2352710_A52084400940658100115421372840918.CEL.gz	0	Reanalyzed by: GSM2351381		GSM2352710	GSM2352711_A52084400940658100115421372840914.CEL	"SUBJ.1544, SLE, week16"	GSM2352711	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.811475409836	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1544	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.059	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352711/suppl/GSM2352711_A52084400940658100115421372840914.CEL.gz	0			GSM2352711	GSM2352712_A52084400940659100115421372840972.CEL	"SUBJ.1544, SLE, week52"	GSM2352712	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.811475409836	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1544	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.059	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352712/suppl/GSM2352712_A52084400940659100115421372840972.CEL.gz	0			GSM2352712	GSM2352713_A52084400939854091415421246947279.CEL	"SUBJ.0200, SLE, baseline"	GSM2352713	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8715846994535	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0200	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 36	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.251	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352713/suppl/GSM2352713_A52084400939854091415421246947279.CEL.gz	0	Reanalyzed by: GSM2351843		GSM2352713	GSM2352714_A52084400939852091415421246947155.CEL	"SUBJ.0200, SLE, week16"	GSM2352714	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8715846994535	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0200	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 36	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.251	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352714/suppl/GSM2352714_A52084400939852091415421246947155.CEL.gz	0			GSM2352714	GSM2352715_A52084400939853091415421246947210.CEL	"SUBJ.0200, SLE, week52"	GSM2352715	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8715846994535	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0200	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 36	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.251	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352715/suppl/GSM2352715_A52084400939853091415421246947210.CEL.gz	0			GSM2352715	GSM2352716_A52084400940548091515421247226933.CEL	"SUBJ.0032, SLE, baseline"	GSM2352716	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0032	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352716/suppl/GSM2352716_A52084400940548091515421247226933.CEL.gz	0	Reanalyzed by: GSM2352426		GSM2352716	GSM2352717_A52084400940549091515421247348533.CEL	"SUBJ.0032, SLE, week16"	GSM2352717	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0032	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352717/suppl/GSM2352717_A52084400940549091515421247348533.CEL.gz	0			GSM2352717	GSM2352718_A52084400940545091515421247226817.CEL	"SUBJ.0032, SLE, week52"	GSM2352718	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0032	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352718/suppl/GSM2352718_A52084400940545091515421247226817.CEL.gz	0			GSM2352718	GSM2352719_A52084400939847091515421247126693.CEL	"SUBJ.1545, SLE, week16"	GSM2352719	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9644808743169	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1545	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.58	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.087	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352719/suppl/GSM2352719_A52084400939847091515421247126693.CEL.gz	0			GSM2352719	GSM2352720_A52084400939497101415421438760471.CEL	"SUBJ.1545, SLE, week52"	GSM2352720	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9644808743169	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1545	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.58	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.087	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352720/suppl/GSM2352720_A52084400939497101415421438760471.CEL.gz	0			GSM2352720	GSM2352721_A52084400939496101415421438761035.CEL	"SUBJ.1833, SLE, baseline"	GSM2352721	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.9369863013698	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1833	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.64	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.269	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352721/suppl/GSM2352721_A52084400939496101415421438761035.CEL.gz	0	Reanalyzed by: GSM2351915		GSM2352721	GSM2352722_A52084400940650100115421364640542.CEL	"SUBJ.1833, SLE, week16"	GSM2352722	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.9369863013698	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1833	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.64	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.269	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352722/suppl/GSM2352722_A52084400940650100115421364640542.CEL.gz	0			GSM2352722	GSM2352723_A52084400939920091515421247126508.CEL	"SUBJ.1833, SLE, week52"	GSM2352723	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.9369863013698	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1833	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.64	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.269	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352723/suppl/GSM2352723_A52084400939920091515421247126508.CEL.gz	0			GSM2352723	GSM2352724_A52084400939921091515421247126563.CEL	"SUBJ.1631, SLE, baseline"	GSM2352724	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9342465753424	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1631	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.266	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352724/suppl/GSM2352724_A52084400939921091515421247126563.CEL.gz	0	Reanalyzed by: GSM2351504		GSM2352724	GSM2352725_A52084400939846091515421247126617.CEL	"SUBJ.1631, SLE, week16"	GSM2352725	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9342465753424	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1631	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.266	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352725/suppl/GSM2352725_A52084400939846091515421247126617.CEL.gz	0			GSM2352725	GSM2352726_A52084400939920091515421247126500.CEL	"SUBJ.1631, SLE, week52"	GSM2352726	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9342465753424	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1631	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.266	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352726/suppl/GSM2352726_A52084400939920091515421247126500.CEL.gz	0			GSM2352726	GSM2352727_A52084400940659100115421372840939.CEL	"SUBJ.1827, SLE, baseline"	GSM2352727	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.4136986301369	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1827	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352727/suppl/GSM2352727_A52084400940659100115421372840939.CEL.gz	0	Reanalyzed by: GSM2351113		GSM2352727	GSM2352728_A52084400940656100115421372840788.CEL	"SUBJ.1827, SLE, week16"	GSM2352728	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.4136986301369	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1827	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352728/suppl/GSM2352728_A52084400940656100115421372840788.CEL.gz	0			GSM2352728	GSM2352729_A52084400940657100115421372840811.CEL	"SUBJ.1827, SLE, week52"	GSM2352729	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.4136986301369	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1827	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352729/suppl/GSM2352729_A52084400940657100115421372840811.CEL.gz	0			GSM2352729	GSM2352730_A52084400939234091415421177246977.CEL	"SUBJ.0445, SLE, baseline"	GSM2352730	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.8986301369863	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0445	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.908	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352730/suppl/GSM2352730_A52084400939234091415421177246977.CEL.gz	0	Reanalyzed by: GSM2351004		GSM2352730	GSM2352731_A52084400939234091415421177246944.CEL	"SUBJ.0445, SLE, week16"	GSM2352731	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.8986301369863	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0445	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.908	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352731/suppl/GSM2352731_A52084400939234091415421177246944.CEL.gz	0			GSM2352731	GSM2352732_A52084400939854091415421246947242.CEL	"SUBJ.0445, SLE, week52"	GSM2352732	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.8986301369863	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0445	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.908	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352732/suppl/GSM2352732_A52084400939854091415421246947242.CEL.gz	0			GSM2352732	GSM2352733_A52084400939212081815420934610981.CEL	"SUBJ.0385, SLE, baseline"	GSM2352733	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.0684931506849	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0385	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.55	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352733/suppl/GSM2352733_A52084400939212081815420934610981.CEL.gz	0	Reanalyzed by: GSM2351406		GSM2352733	GSM2352734_A52084400939497101415421438760460.CEL	"SUBJ.0385, SLE, week16"	GSM2352734	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.0684931506849	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0385	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.55	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352734/suppl/GSM2352734_A52084400939497101415421438760460.CEL.gz	0			GSM2352734	GSM2352735_A52084400939213081815420934611055.CEL	"SUBJ.0385, SLE, week52"	GSM2352735	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.0684931506849	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0385	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.55	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352735/suppl/GSM2352735_A52084400939213081815420934611055.CEL.gz	0			GSM2352735	GSM2352736_A52084400939852091415421246947139.CEL	"SUBJ.1128, SLE, baseline"	GSM2352736	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8191780821917	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1128	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.273	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352736/suppl/GSM2352736_A52084400939852091415421246947139.CEL.gz	0	Reanalyzed by: GSM2351473		GSM2352736	GSM2352737_A52084400939853091415421246947218.CEL	"SUBJ.1128, SLE, week16"	GSM2352737	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8191780821917	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1128	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.273	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352737/suppl/GSM2352737_A52084400939853091415421246947218.CEL.gz	0			GSM2352737	GSM2352738_A52084400939854091415421246947286.CEL	"SUBJ.1128, SLE, week52"	GSM2352738	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8191780821917	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1128	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.273	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352738/suppl/GSM2352738_A52084400939854091415421246947286.CEL.gz	0			GSM2352738	GSM2352739_A52084400939115082215421026196707.CEL	"SUBJ.0423, SLE, baseline"	GSM2352739	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.931506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0423	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.42	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352739/suppl/GSM2352739_A52084400939115082215421026196707.CEL.gz	0	Reanalyzed by: GSM2352393		GSM2352739	GSM2352740_A52084400939116082215421026196723.CEL	"SUBJ.0423, SLE, week16"	GSM2352740	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.931506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0423	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.42	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352740/suppl/GSM2352740_A52084400939116082215421026196723.CEL.gz	0			GSM2352740	GSM2352741_A52084400939907082115420971516282.CEL	"SUBJ.0423, SLE, week52"	GSM2352741	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.931506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0423	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.42	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352741/suppl/GSM2352741_A52084400939907082115420971516282.CEL.gz	0			GSM2352741	GSM2352742_A52084400940544091515421247226730.CEL	"SUBJ.1266, SLE, baseline"	GSM2352742	sledai_at_baseline: 22	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3369863013698	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1266	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 35	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.636	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352742/suppl/GSM2352742_A52084400940544091515421247226730.CEL.gz	0	Reanalyzed by: GSM2352029		GSM2352742	GSM2352743_A52084400940545091515421247226789.CEL	"SUBJ.1266, SLE, week16"	GSM2352743	sledai_at_baseline: 22	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3369863013698	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1266	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 35	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.636	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352743/suppl/GSM2352743_A52084400940545091515421247226789.CEL.gz	0			GSM2352743	GSM2352744_A52084400940544091515421247226753.CEL	"SUBJ.1266, SLE, week52"	GSM2352744	sledai_at_baseline: 22	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3369863013698	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1266	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 35	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.636	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352744/suppl/GSM2352744_A52084400940544091515421247226753.CEL.gz	0			GSM2352744	GSM2352745_A52084400939228091315421177045841.CEL	"SUBJ.1191, SLE, baseline"	GSM2352745	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7267759562841	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1191	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.257	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352745/suppl/GSM2352745_A52084400939228091315421177045841.CEL.gz	0	Reanalyzed by: GSM2351344		GSM2352745	GSM2352746_A52084400939842091415421247047362.CEL	"SUBJ.1191, SLE, week16"	GSM2352746	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7267759562841	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1191	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.257	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352746/suppl/GSM2352746_A52084400939842091415421247047362.CEL.gz	0			GSM2352746	GSM2352747_A52084400939228091315421177045871.CEL	"SUBJ.1191, SLE, week52"	GSM2352747	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7267759562841	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1191	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.257	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352747/suppl/GSM2352747_A52084400939228091315421177045871.CEL.gz	0			GSM2352747	GSM2352748_A52084400940069100715421373649369.CEL	"SUBJ.1462, SLE, baseline"	GSM2352748	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.2602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1462	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 153	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.511	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.175	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352748/suppl/GSM2352748_A52084400940069100715421373649369.CEL.gz	0	Reanalyzed by: GSM2352504		GSM2352748	GSM2352749_A52084400940119100915421438150870.CEL	"SUBJ.1462, SLE, week16"	GSM2352749	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.2602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1462	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 153	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.511	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.175	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352749/suppl/GSM2352749_A52084400940119100915421438150870.CEL.gz	0			GSM2352749	GSM2352750_A52084400940118100915421438150775.CEL	"SUBJ.1462, SLE, week52"	GSM2352750	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.2602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1462	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 153	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.511	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.175	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352750/suppl/GSM2352750_A52084400940118100915421438150775.CEL.gz	0			GSM2352750	GSM2352751_A52084400939214081815420934611074.CEL	"SUBJ.1813, SLE, baseline"	GSM2352751	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.8169398907103	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1813	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.331	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352751/suppl/GSM2352751_A52084400939214081815420934611074.CEL.gz	0	Reanalyzed by: GSM2351236		GSM2352751	GSM2352752_A52084400939215081815420934611143.CEL	"SUBJ.1813, SLE, week16"	GSM2352752	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.8169398907103	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1813	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.331	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352752/suppl/GSM2352752_A52084400939215081815420934611143.CEL.gz	0			GSM2352752	GSM2352753_A52084400939215081815420934611129.CEL	"SUBJ.1813, SLE, week52"	GSM2352753	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.8169398907103	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1813	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.331	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352753/suppl/GSM2352753_A52084400939215081815420934611129.CEL.gz	0			GSM2352753	GSM2352754_A52084400939846091515421247126639.CEL	"SUBJ.0421, SLE, baseline"	GSM2352754	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7021857923497	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0421	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.877	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.204	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352754/suppl/GSM2352754_A52084400939846091515421247126639.CEL.gz	0	Reanalyzed by: GSM2351581		GSM2352754	GSM2352755_A52084400939846091515421247126610.CEL	"SUBJ.0421, SLE, week16"	GSM2352755	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7021857923497	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0421	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.877	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.204	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352755/suppl/GSM2352755_A52084400939846091515421247126610.CEL.gz	0			GSM2352755	GSM2352756_A52084400939921091515421247126578.CEL	"SUBJ.0421, SLE, week52"	GSM2352756	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7021857923497	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0421	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.877	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.204	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352756/suppl/GSM2352756_A52084400939921091515421247126578.CEL.gz	0			GSM2352756	GSM2352757_A52084400939212081815420934610982.CEL	"SUBJ.0394, SLE, baseline"	GSM2352757	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6994535519125	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0394	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.988	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352757/suppl/GSM2352757_A52084400939212081815420934610982.CEL.gz	0	Reanalyzed by: GSM2352026		GSM2352757	GSM2352758_A52084400939215081815420934611131.CEL	"SUBJ.0394, SLE, week16"	GSM2352758	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6994535519125	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0394	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.988	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352758/suppl/GSM2352758_A52084400939215081815420934611131.CEL.gz	0			GSM2352758	GSM2352759_A52084400939215081815420934611173.CEL	"SUBJ.0394, SLE, week52"	GSM2352759	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6994535519125	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0394	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.988	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352759/suppl/GSM2352759_A52084400939215081815420934611173.CEL.gz	0			GSM2352759	GSM2352760_A52084400940544091515421247226758.CEL	"SUBJ.1551, SLE, baseline"	GSM2352760	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1551	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 207	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352760/suppl/GSM2352760_A52084400940544091515421247226758.CEL.gz	0	Reanalyzed by: GSM2352449		GSM2352760	GSM2352761_A52084400940544091515421247226745.CEL	"SUBJ.1551, SLE, week16"	GSM2352761	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1551	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 207	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352761/suppl/GSM2352761_A52084400940544091515421247226745.CEL.gz	0			GSM2352761	GSM2352762_A52084400940548091515421247226930.CEL	"SUBJ.1551, SLE, week52"	GSM2352762	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1551	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 207	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352762/suppl/GSM2352762_A52084400940548091515421247226930.CEL.gz	0			GSM2352762	GSM2352763_A52084400939232091415421177246866.CEL	"SUBJ.1099, SLE, baseline"	GSM2352763	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9424657534246	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1099	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 98	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352763/suppl/GSM2352763_A52084400939232091415421177246866.CEL.gz	0	Reanalyzed by: GSM2351142		GSM2352763	GSM2352764_A52084400939845091415421247047543.CEL	"SUBJ.1099, SLE, week16"	GSM2352764	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9424657534246	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1099	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 98	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352764/suppl/GSM2352764_A52084400939845091415421247047543.CEL.gz	0			GSM2352764	GSM2352765_A52084400939853091415421246947189.CEL	"SUBJ.1099, SLE, week52"	GSM2352765	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9424657534246	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1099	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 98	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352765/suppl/GSM2352765_A52084400939853091415421246947189.CEL.gz	0			GSM2352765	GSM2352766_A52084400939272081315420891403969.CEL	"SUBJ.0765, SLE, baseline"	GSM2352766	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.7568306010929	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0765	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352766/suppl/GSM2352766_A52084400939272081315420891403969.CEL.gz	0	Reanalyzed by: GSM2351925		GSM2352766	GSM2352767_A52084400939212081815420934610971.CEL	"SUBJ.0765, SLE, week16"	GSM2352767	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.7568306010929	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0765	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352767/suppl/GSM2352767_A52084400939212081815420934610971.CEL.gz	0			GSM2352767	GSM2352768_A52084400939272081315420891403965.CEL	"SUBJ.0765, SLE, week52"	GSM2352768	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.7568306010929	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0765	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 143	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352768/suppl/GSM2352768_A52084400939272081315420891403965.CEL.gz	0			GSM2352768	GSM2352769_A52084400940546091515421247226861.CEL	"SUBJ.0285, SLE, baseline"	GSM2352769	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8739726027397	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0285	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352769/suppl/GSM2352769_A52084400940546091515421247226861.CEL.gz	0	Reanalyzed by: GSM2351921		GSM2352769	GSM2352770_A52084400939847091515421247126690.CEL	"SUBJ.0285, SLE, week16"	GSM2352770	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8739726027397	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0285	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352770/suppl/GSM2352770_A52084400939847091515421247126690.CEL.gz	0			GSM2352770	GSM2352771_A52084400940545091515421247226822.CEL	"SUBJ.0285, SLE, week52"	GSM2352771	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8739726027397	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0285	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352771/suppl/GSM2352771_A52084400940545091515421247226822.CEL.gz	0			GSM2352771	GSM2352772_A52084400939907082115420971516265.CEL	"SUBJ.0800, SLE, baseline"	GSM2352772	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8715846994535	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0800	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): --	c3_at_baseline (g/l): --	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): --	c4_at_baseline (g/l): --	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352772/suppl/GSM2352772_A52084400939907082115420971516265.CEL.gz	0	Reanalyzed by: GSM2352488		GSM2352772	GSM2352773_A52084400939114082215421026196644.CEL	"SUBJ.0800, SLE, week16"	GSM2352773	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8715846994535	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0800	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): --	c3_at_baseline (g/l): --	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): --	c4_at_baseline (g/l): --	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352773/suppl/GSM2352773_A52084400939114082215421026196644.CEL.gz	0			GSM2352773	GSM2352774_A52084400939116082215421026196747.CEL	"SUBJ.0800, SLE, week52"	GSM2352774	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8715846994535	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0800	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): --	c3_at_baseline (g/l): --	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): --	c4_at_baseline (g/l): --	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352774/suppl/GSM2352774_A52084400939116082215421026196747.CEL.gz	0			GSM2352774	GSM2352775_A52084400939846091515421247126652.CEL	"SUBJ.0001, SLE, baseline"	GSM2352775	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.7671232876712	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0001	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 233	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.961	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.098	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352775/suppl/GSM2352775_A52084400939846091515421247126652.CEL.gz	0	Reanalyzed by: GSM2351464		GSM2352775	GSM2352776_A52084400939847091515421247126687.CEL	"SUBJ.0001, SLE, week16"	GSM2352776	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.7671232876712	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0001	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 233	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.961	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.098	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352776/suppl/GSM2352776_A52084400939847091515421247126687.CEL.gz	0			GSM2352776	GSM2352777_A52084400939847091515421247126682.CEL	"SUBJ.0001, SLE, week52"	GSM2352777	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.7671232876712	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0001	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 233	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.961	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.098	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352777/suppl/GSM2352777_A52084400939847091515421247126682.CEL.gz	0			GSM2352777	GSM2352778_A52084400939852091415421246947151.CEL	"SUBJ.1024, SLE, baseline"	GSM2352778	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.4767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1024	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.797	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.146	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352778/suppl/GSM2352778_A52084400939852091415421246947151.CEL.gz	0	Reanalyzed by: GSM2350972		GSM2352778	GSM2352779_A52084400939852091415421246947150.CEL	"SUBJ.1024, SLE, week16"	GSM2352779	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.4767123287671	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1024	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.797	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.146	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352779/suppl/GSM2352779_A52084400939852091415421246947150.CEL.gz	0			GSM2352779	GSM2352780_A52084400939855091415421246947313.CEL	"SUBJ.1024, SLE, week52"	GSM2352780	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.4767123287671	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1024	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.797	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.146	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352780/suppl/GSM2352780_A52084400939855091415421246947313.CEL.gz	0			GSM2352780	GSM2352781_A52084400939921091515421247126552.CEL	"SUBJ.0476, SLE, baseline"	GSM2352781	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5835616438356	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0476	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.751	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.052	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352781/suppl/GSM2352781_A52084400939921091515421247126552.CEL.gz	0	Reanalyzed by: GSM2351745		GSM2352781	GSM2352782_A52084400940657100115421372840856.CEL	"SUBJ.0476, SLE, week16"	GSM2352782	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5835616438356	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0476	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.751	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.052	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352782/suppl/GSM2352782_A52084400940657100115421372840856.CEL.gz	0			GSM2352782	GSM2352783_A52084400939496101415421438761037.CEL	"SUBJ.0476, SLE, week52"	GSM2352783	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5835616438356	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0476	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.751	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.052	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352783/suppl/GSM2352783_A52084400939496101415421438761037.CEL.gz	0			GSM2352783	GSM2352784_A52084400939854091415421246947272.CEL	"SUBJ.1467, SLE, baseline"	GSM2352784	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.1643835616438	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1467	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352784/suppl/GSM2352784_A52084400939854091415421246947272.CEL.gz	0	Reanalyzed by: GSM2351411		GSM2352784	GSM2352785_A52084400939852091415421246947124.CEL	"SUBJ.1467, SLE, week16"	GSM2352785	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.1643835616438	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1467	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352785/suppl/GSM2352785_A52084400939852091415421246947124.CEL.gz	0			GSM2352785	GSM2352786_A52084400939854091415421246947263.CEL	"SUBJ.1467, SLE, week52"	GSM2352786	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.1643835616438	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1467	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352786/suppl/GSM2352786_A52084400939854091415421246947263.CEL.gz	0			GSM2352786	GSM2352787_A52084400939116082215421026196755.CEL	"SUBJ.0265, SLE, baseline"	GSM2352787	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.972602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0265	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352787/suppl/GSM2352787_A52084400939116082215421026196755.CEL.gz	0	Reanalyzed by: GSM2351804		GSM2352787	GSM2352788_A52084400939116082215421026196742.CEL	"SUBJ.0265, SLE, week16"	GSM2352788	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.972602739726	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0265	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352788/suppl/GSM2352788_A52084400939116082215421026196742.CEL.gz	0			GSM2352788	GSM2352789_A52084400939115082215421026196684.CEL	"SUBJ.0265, SLE, week52"	GSM2352789	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.972602739726	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0265	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352789/suppl/GSM2352789_A52084400939115082215421026196684.CEL.gz	0			GSM2352789	GSM2352790_A52084400939853091415421246947188.CEL	"SUBJ.0090, SLE, baseline"	GSM2352790	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0090	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.735	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352790/suppl/GSM2352790_A52084400939853091415421246947188.CEL.gz	0	Reanalyzed by: GSM2351937		GSM2352790	GSM2352791_A52084400939842091415421247047376.CEL	"SUBJ.0090, SLE, week16"	GSM2352791	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7732240437158	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0090	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.735	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352791/suppl/GSM2352791_A52084400939842091415421247047376.CEL.gz	0			GSM2352791	GSM2352792_A52084400939854091415421246947284.CEL	"SUBJ.0090, SLE, week52"	GSM2352792	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7732240437158	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0090	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.735	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352792/suppl/GSM2352792_A52084400939854091415421246947284.CEL.gz	0			GSM2352792	GSM2352793_A52084400939233091415421177246918.CEL	"SUBJ.0365, SLE, baseline"	GSM2352793	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.8524590163934	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0365	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.88	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.333	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352793/suppl/GSM2352793_A52084400939233091415421177246918.CEL.gz	0	Reanalyzed by: GSM2352084		GSM2352793	GSM2352794_A52084400939116082215421026196763.CEL	"SUBJ.0365, SLE, week16"	GSM2352794	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.8524590163934	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0365	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.88	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.333	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352794/suppl/GSM2352794_A52084400939116082215421026196763.CEL.gz	0			GSM2352794	GSM2352795_A52084400939853091415421246947204.CEL	"SUBJ.0365, SLE, week52"	GSM2352795	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.8524590163934	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0365	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.88	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.333	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352795/suppl/GSM2352795_A52084400939853091415421246947204.CEL.gz	0			GSM2352795	GSM2352796_A52084400939846091515421247126613.CEL	"SUBJ.1797, SLE, baseline"	GSM2352796	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1797	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.137	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352796/suppl/GSM2352796_A52084400939846091515421247126613.CEL.gz	0	Reanalyzed by: GSM2351404		GSM2352796	GSM2352797_A52084400939846091515421247126627.CEL	"SUBJ.1797, SLE, week16"	GSM2352797	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7732240437158	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1797	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.137	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352797/suppl/GSM2352797_A52084400939846091515421247126627.CEL.gz	0			GSM2352797	GSM2352798_A52084400939921091515421247126577.CEL	"SUBJ.1797, SLE, week52"	GSM2352798	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7732240437158	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1797	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.137	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352798/suppl/GSM2352798_A52084400939921091515421247126577.CEL.gz	0			GSM2352798	GSM2352799_A52084400939852091415421246947137.CEL	"SUBJ.0741, SLE, baseline"	GSM2352799	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.2109589041096	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0741	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.157	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352799/suppl/GSM2352799_A52084400939852091415421246947137.CEL.gz	0	Reanalyzed by: GSM2351739		GSM2352799	GSM2352800_A52084400939852091415421246947132.CEL	"SUBJ.0741, SLE, week16"	GSM2352800	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.2109589041096	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0741	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.157	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352800/suppl/GSM2352800_A52084400939852091415421246947132.CEL.gz	0			GSM2352800	GSM2352801_A52084400939854091415421246947245.CEL	"SUBJ.0741, SLE, week52"	GSM2352801	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.2109589041096	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0741	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.157	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352801/suppl/GSM2352801_A52084400939854091415421246947245.CEL.gz	0			GSM2352801	GSM2352802_A52084400939846091515421247126622.CEL	"SUBJ.1705, SLE, baseline"	GSM2352802	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7568306010929	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1705	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.934	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352802/suppl/GSM2352802_A52084400939846091515421247126622.CEL.gz	0	Reanalyzed by: GSM2351536		GSM2352802	GSM2352803_A52084400939920091515421247126532.CEL	"SUBJ.1705, SLE, week16"	GSM2352803	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7568306010929	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1705	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.934	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352803/suppl/GSM2352803_A52084400939920091515421247126532.CEL.gz	0			GSM2352803	GSM2352804_A52084400939846091515421247126631.CEL	"SUBJ.1705, SLE, week52"	GSM2352804	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7568306010929	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1705	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.934	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352804/suppl/GSM2352804_A52084400939846091515421247126631.CEL.gz	0			GSM2352804	GSM2352805_A52084400939116082215421026196759.CEL	"SUBJ.1795, SLE, baseline"	GSM2352805	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1795	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.281	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352805/suppl/GSM2352805_A52084400939116082215421026196759.CEL.gz	0	Reanalyzed by: GSM2351624		GSM2352805	GSM2352806_A52084400939213081815420934611040.CEL	"SUBJ.1795, SLE, week16"	GSM2352806	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1795	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.281	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352806/suppl/GSM2352806_A52084400939213081815420934611040.CEL.gz	0			GSM2352806	GSM2352807_A52084400939115082215421026196699.CEL	"SUBJ.1795, SLE, week52"	GSM2352807	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1795	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.18	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.281	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352807/suppl/GSM2352807_A52084400939115082215421026196699.CEL.gz	0			GSM2352807	GSM2352808_A52084400939230091315421177046049.CEL	"SUBJ.0858, SLE, baseline"	GSM2352808	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0858	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.848	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.133	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352808/suppl/GSM2352808_A52084400939230091315421177046049.CEL.gz	0	Reanalyzed by: GSM2351733		GSM2352808	GSM2352809_A52084400939230091315421177046054.CEL	"SUBJ.0858, SLE, week16"	GSM2352809	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8767123287671	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0858	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.848	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.133	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352809/suppl/GSM2352809_A52084400939230091315421177046054.CEL.gz	0			GSM2352809	GSM2352810_A52084400939231091315421177046171.CEL	"SUBJ.0858, SLE, week52"	GSM2352810	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8767123287671	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0858	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.848	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.133	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352810/suppl/GSM2352810_A52084400939231091315421177046171.CEL.gz	0			GSM2352810	GSM2352811_A52084400940070100715421373649398.CEL	"SUBJ.0513, SLE, baseline"	GSM2352811	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.9616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0513	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 131	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.368	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352811/suppl/GSM2352811_A52084400940070100715421373649398.CEL.gz	0	Reanalyzed by: GSM2351052		GSM2352811	GSM2352812_A52084400940081100815421437950428.CEL	"SUBJ.0513, SLE, week16"	GSM2352812	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.9616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0513	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 131	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.368	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352812/suppl/GSM2352812_A52084400940081100815421437950428.CEL.gz	0			GSM2352812	GSM2352813_A52084400940069100715421373649380.CEL	"SUBJ.0513, SLE, week52"	GSM2352813	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.9616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0513	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 131	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.368	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352813/suppl/GSM2352813_A52084400940069100715421373649380.CEL.gz	0			GSM2352813	GSM2352814_A52084400939231091315421177046192.CEL	"SUBJ.1749, SLE, baseline"	GSM2352814	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6493150684931	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1749	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.197	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352814/suppl/GSM2352814_A52084400939231091315421177046192.CEL.gz	0	Reanalyzed by: GSM2352018		GSM2352814	GSM2352815_A52084400939231091315421177046208.CEL	"SUBJ.1749, SLE, week16"	GSM2352815	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6493150684931	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1749	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.197	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352815/suppl/GSM2352815_A52084400939231091315421177046208.CEL.gz	0			GSM2352815	GSM2352816_A52084400939231091315421177046209.CEL	"SUBJ.1749, SLE, week52"	GSM2352816	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6493150684931	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1749	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.197	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352816/suppl/GSM2352816_A52084400939231091315421177046209.CEL.gz	0			GSM2352816	GSM2352817_A52084400940548091515421247226939.CEL	"SUBJ.0359, SLE, baseline"	GSM2352817	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8169398907103	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0359	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.284	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352817/suppl/GSM2352817_A52084400940548091515421247226939.CEL.gz	0	Reanalyzed by: GSM2351703		GSM2352817	GSM2352818_A52084400940546091515421247226897.CEL	"SUBJ.0359, SLE, week16"	GSM2352818	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8169398907103	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0359	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.284	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352818/suppl/GSM2352818_A52084400940546091515421247226897.CEL.gz	0			GSM2352818	GSM2352819_A52084400940548091515421247226924.CEL	"SUBJ.0359, SLE, week52"	GSM2352819	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.8169398907103	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0359	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.284	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352819/suppl/GSM2352819_A52084400940548091515421247226924.CEL.gz	0			GSM2352819	GSM2352820_A52084400940545091515421247226809.CEL	"SUBJ.1258, SLE, baseline"	GSM2352820	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.7972602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1258	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 188	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.199	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352820/suppl/GSM2352820_A52084400940545091515421247226809.CEL.gz	0	Reanalyzed by: GSM2351040		GSM2352820	GSM2352821_A52084400940549091515421247348557.CEL	"SUBJ.1258, SLE, week16"	GSM2352821	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.7972602739726	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1258	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 188	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.199	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352821/suppl/GSM2352821_A52084400940549091515421247348557.CEL.gz	0			GSM2352821	GSM2352822_A52084400940550091515421247348624.CEL	"SUBJ.1258, SLE, week52"	GSM2352822	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.7972602739726	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1258	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 188	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.918	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.199	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352822/suppl/GSM2352822_A52084400940550091515421247348624.CEL.gz	0			GSM2352822	GSM2352823_A52084400939843091415421247047421.CEL	"SUBJ.1677, SLE, baseline"	GSM2352823	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.0904109589041	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1677	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 46	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.178	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352823/suppl/GSM2352823_A52084400939843091415421247047421.CEL.gz	0	Reanalyzed by: GSM2351666		GSM2352823	GSM2352824_A52084400939853091415421246947214.CEL	"SUBJ.1677, SLE, week16"	GSM2352824	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.0904109589041	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1677	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 46	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.178	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352824/suppl/GSM2352824_A52084400939853091415421246947214.CEL.gz	0			GSM2352824	GSM2352825_A52084400939845091415421247047551.CEL	"SUBJ.1677, SLE, week52"	GSM2352825	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.0904109589041	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1677	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 46	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.178	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352825/suppl/GSM2352825_A52084400939845091415421247047551.CEL.gz	0			GSM2352825	GSM2352826_A52084400939269081315420891403783.CEL	"SUBJ.1663, SLE, baseline"	GSM2352826	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.75956284153	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1663	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.212	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352826/suppl/GSM2352826_A52084400939269081315420891403783.CEL.gz	0	Reanalyzed by: GSM2352166		GSM2352826	GSM2352827_A52084400939272081315420891403980.CEL	"SUBJ.1663, SLE, week16"	GSM2352827	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.75956284153	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1663	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.212	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352827/suppl/GSM2352827_A52084400939272081315420891403980.CEL.gz	0			GSM2352827	GSM2352828_A52084400939269081315420891403789.CEL	"SUBJ.1663, SLE, week52"	GSM2352828	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.75956284153	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1663	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.212	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352828/suppl/GSM2352828_A52084400939269081315420891403789.CEL.gz	0			GSM2352828	GSM2352829_A52084400940659100115421372840960.CEL	"SUBJ.0251, SLE, baseline"	GSM2352829	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.5342465753424	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0251	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352829/suppl/GSM2352829_A52084400940659100115421372840960.CEL.gz	0	Reanalyzed by: GSM2352542		GSM2352829	GSM2352830_A52084400940659100115421372840968.CEL	"SUBJ.0251, SLE, week16"	GSM2352830	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.5342465753424	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0251	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352830/suppl/GSM2352830_A52084400940659100115421372840968.CEL.gz	0			GSM2352830	GSM2352831_A52084400940656100115421372840767.CEL	"SUBJ.0251, SLE, week52"	GSM2352831	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.5342465753424	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0251	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352831/suppl/GSM2352831_A52084400940656100115421372840767.CEL.gz	0			GSM2352831	GSM2352832_A52084400940545091515421247226824.CEL	"SUBJ.1741, SLE, baseline"	GSM2352832	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8879781420765	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1741	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.695	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352832/suppl/GSM2352832_A52084400940545091515421247226824.CEL.gz	0	Reanalyzed by: GSM2351497		GSM2352832	GSM2352833_A52084400939921091515421247126594.CEL	"SUBJ.1741, SLE, week16"	GSM2352833	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8879781420765	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1741	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.695	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352833/suppl/GSM2352833_A52084400939921091515421247126594.CEL.gz	0			GSM2352833	GSM2352834_A52084400940545091515421247226827.CEL	"SUBJ.1741, SLE, week52"	GSM2352834	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8879781420765	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1741	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.695	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352834/suppl/GSM2352834_A52084400940545091515421247226827.CEL.gz	0			GSM2352834	GSM2352835_A52084400939852091415421246947156.CEL	"SUBJ.1119, SLE, baseline"	GSM2352835	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8142076502732	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1119	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352835/suppl/GSM2352835_A52084400939852091415421246947156.CEL.gz	0	Reanalyzed by: GSM2350983		GSM2352835	GSM2352836_A52084400939854091415421246947260.CEL	"SUBJ.1119, SLE, week16"	GSM2352836	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8142076502732	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1119	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352836/suppl/GSM2352836_A52084400939854091415421246947260.CEL.gz	0			GSM2352836	GSM2352837_A52084400939855091415421246947332.CEL	"SUBJ.1119, SLE, week52"	GSM2352837	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8142076502732	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1119	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.219	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352837/suppl/GSM2352837_A52084400939855091415421246947332.CEL.gz	0			GSM2352837	GSM2352838_A52084400939844091415421247047489.CEL	"SUBJ.0739, SLE, baseline"	GSM2352838	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6054794520548	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0739	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 166	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.467	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352838/suppl/GSM2352838_A52084400939844091415421247047489.CEL.gz	0	Reanalyzed by: GSM2351912		GSM2352838	GSM2352839_A52084400939234091415421177246982.CEL	"SUBJ.0739, SLE, week16"	GSM2352839	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6054794520548	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0739	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 166	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.467	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352839/suppl/GSM2352839_A52084400939234091415421177246982.CEL.gz	0			GSM2352839	GSM2352840_A52084400939845091415421247047550.CEL	"SUBJ.0739, SLE, week52"	GSM2352840	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6054794520548	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0739	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 166	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.467	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352840/suppl/GSM2352840_A52084400939845091415421247047550.CEL.gz	0			GSM2352840	GSM2352841_A52084400939115082215421026196703.CEL	"SUBJ.0559, SLE, baseline"	GSM2352841	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6939890710382	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0559	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352841/suppl/GSM2352841_A52084400939115082215421026196703.CEL.gz	0	Reanalyzed by: GSM2352295		GSM2352841	GSM2352842_A52084400939114082215421026196629.CEL	"SUBJ.0559, SLE, week16"	GSM2352842	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6939890710382	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0559	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352842/suppl/GSM2352842_A52084400939114082215421026196629.CEL.gz	0			GSM2352842	GSM2352843_A52084400939115082215421026196686.CEL	"SUBJ.0559, SLE, week52"	GSM2352843	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6939890710382	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0559	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.228	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352843/suppl/GSM2352843_A52084400939115082215421026196686.CEL.gz	0			GSM2352843	GSM2352844_A52084400939212081815420934610962.CEL	"SUBJ.0237, SLE, baseline"	GSM2352844	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7021857923497	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0237	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 62	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.821	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352844/suppl/GSM2352844_A52084400939212081815420934610962.CEL.gz	0	Reanalyzed by: GSM2351848		GSM2352844	GSM2352845_A52084400939213081815420934611022.CEL	"SUBJ.0237, SLE, week16"	GSM2352845	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7021857923497	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0237	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 62	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.821	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352845/suppl/GSM2352845_A52084400939213081815420934611022.CEL.gz	0			GSM2352845	GSM2352846_A52084400939212081815420934610992.CEL	"SUBJ.0237, SLE, week52"	GSM2352846	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7021857923497	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0237	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 62	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.821	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352846/suppl/GSM2352846_A52084400939212081815420934610992.CEL.gz	0			GSM2352846	GSM2352847_A52084400939854091415421246947255.CEL	"SUBJ.0350, SLE, baseline"	GSM2352847	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.2630136986301	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0350	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.43	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.136	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352847/suppl/GSM2352847_A52084400939854091415421246947255.CEL.gz	0	Reanalyzed by: GSM2352179		GSM2352847	GSM2352848_A52084400939852091415421246947126.CEL	"SUBJ.0350, SLE, week16"	GSM2352848	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.2630136986301	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0350	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.43	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.136	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352848/suppl/GSM2352848_A52084400939852091415421246947126.CEL.gz	0			GSM2352848	GSM2352849_A52084400939855091415421246947341.CEL	"SUBJ.0350, SLE, week52"	GSM2352849	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.2630136986301	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0350	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.43	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.136	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352849/suppl/GSM2352849_A52084400939855091415421246947341.CEL.gz	0			GSM2352849	GSM2352850_A52084400939233091415421177246885.CEL	"SUBJ.1154, SLE, baseline"	GSM2352850	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.2191780821917	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1154	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 31	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.96	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.424	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352850/suppl/GSM2352850_A52084400939233091415421177246885.CEL.gz	0	Reanalyzed by: GSM2351185		GSM2352850	GSM2352851_A52084400939233091415421177246924.CEL	"SUBJ.1154, SLE, week52"	GSM2352851	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.2191780821917	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1154	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 31	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.96	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.424	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352851/suppl/GSM2352851_A52084400939233091415421177246924.CEL.gz	0			GSM2352851	GSM2352852_A52084400940546091515421247226886.CEL	"SUBJ.1533, SLE, baseline"	GSM2352852	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6027397260274	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1533	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.08	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.196	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352852/suppl/GSM2352852_A52084400940546091515421247226886.CEL.gz	0	Reanalyzed by: GSM2350947		GSM2352852	GSM2352853_A52084400940546091515421247226857.CEL	"SUBJ.1533, SLE, week16"	GSM2352853	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6027397260274	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1533	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.08	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.196	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352853/suppl/GSM2352853_A52084400940546091515421247226857.CEL.gz	0			GSM2352853	GSM2352854_A52084400940546091515421247226893.CEL	"SUBJ.1533, SLE, week52"	GSM2352854	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6027397260274	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1533	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.08	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.196	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352854/suppl/GSM2352854_A52084400940546091515421247226893.CEL.gz	0			GSM2352854	GSM2352855_A52084400939115082215421026196672.CEL	"SUBJ.1091, SLE, baseline"	GSM2352855	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.131506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1091	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.17	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352855/suppl/GSM2352855_A52084400939115082215421026196672.CEL.gz	0	Reanalyzed by: GSM2351615		GSM2352855	GSM2352856_A52084400939114082215421026196619.CEL	"SUBJ.1091, SLE, week16"	GSM2352856	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.131506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1091	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.17	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352856/suppl/GSM2352856_A52084400939114082215421026196619.CEL.gz	0			GSM2352856	GSM2352857_A52084400939114082215421026196609.CEL	"SUBJ.1091, SLE, week52"	GSM2352857	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.131506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1091	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.17	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352857/suppl/GSM2352857_A52084400939114082215421026196609.CEL.gz	0			GSM2352857	GSM2352858_A52084400939852091415421246947153.CEL	"SUBJ.1268, SLE, baseline"	GSM2352858	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.4301369863013	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1268	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352858/suppl/GSM2352858_A52084400939852091415421246947153.CEL.gz	0	Reanalyzed by: GSM2351145		GSM2352858	GSM2352859_A52084400939852091415421246947138.CEL	"SUBJ.1268, SLE, week16"	GSM2352859	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.4301369863013	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1268	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352859/suppl/GSM2352859_A52084400939852091415421246947138.CEL.gz	0			GSM2352859	GSM2352860_A52084400939852091415421246947164.CEL	"SUBJ.1268, SLE, week52"	GSM2352860	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.4301369863013	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1268	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 119	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352860/suppl/GSM2352860_A52084400939852091415421246947164.CEL.gz	0			GSM2352860	GSM2352861_A52084400939842091415421247047406.CEL	"SUBJ.0046, SLE, baseline"	GSM2352861	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.3780821917808	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0046	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352861/suppl/GSM2352861_A52084400939842091415421247047406.CEL.gz	0	Reanalyzed by: GSM2352417		GSM2352861	GSM2352862_A52084400939231091315421177046200.CEL	"SUBJ.0046, SLE, week16"	GSM2352862	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.3780821917808	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0046	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352862/suppl/GSM2352862_A52084400939231091315421177046200.CEL.gz	0			GSM2352862	GSM2352863_A52084400939844091415421247047508.CEL	"SUBJ.0046, SLE, week52"	GSM2352863	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.3780821917808	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0046	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 89	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352863/suppl/GSM2352863_A52084400939844091415421247047508.CEL.gz	0			GSM2352863	GSM2352864_A52084400939115082215421026196702.CEL	"SUBJ.1454, SLE, baseline"	GSM2352864	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.6410958904109	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1454	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352864/suppl/GSM2352864_A52084400939115082215421026196702.CEL.gz	0	Reanalyzed by: GSM2352161		GSM2352864	GSM2352865_A52084400939907082115420971516303.CEL	"SUBJ.1454, SLE, week16"	GSM2352865	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.6410958904109	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1454	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352865/suppl/GSM2352865_A52084400939907082115420971516303.CEL.gz	0			GSM2352865	GSM2352866_A52084400939114082215421026196649.CEL	"SUBJ.1454, SLE, week52"	GSM2352866	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.6410958904109	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1454	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352866/suppl/GSM2352866_A52084400939114082215421026196649.CEL.gz	0			GSM2352866	GSM2352867_A52084400940550091515421247348598.CEL	"SUBJ.0338, SLE, baseline"	GSM2352867	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8743169398907	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0338	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.119	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352867/suppl/GSM2352867_A52084400940550091515421247348598.CEL.gz	0	Reanalyzed by: GSM2351002		GSM2352867	GSM2352868_A52084400940550091515421247348611.CEL	"SUBJ.0338, SLE, week16"	GSM2352868	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8743169398907	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0338	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.119	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352868/suppl/GSM2352868_A52084400940550091515421247348611.CEL.gz	0			GSM2352868	GSM2352869_A52084400940546091515421247226884.CEL	"SUBJ.0338, SLE, week52"	GSM2352869	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8743169398907	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0338	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.119	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352869/suppl/GSM2352869_A52084400940546091515421247226884.CEL.gz	0			GSM2352869	GSM2352870_A52084400939854091415421246947254.CEL	"SUBJ.1452, SLE, baseline"	GSM2352870	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1452	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.763	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352870/suppl/GSM2352870_A52084400939854091415421246947254.CEL.gz	0	Reanalyzed by: GSM2351760		GSM2352870	GSM2352871_A52084400939854091415421246947278.CEL	"SUBJ.1452, SLE, week16"	GSM2352871	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.7732240437158	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1452	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.763	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352871/suppl/GSM2352871_A52084400939854091415421246947278.CEL.gz	0			GSM2352871	GSM2352872_A52084400939854091415421246947280.CEL	"SUBJ.1452, SLE, week52"	GSM2352872	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.7732240437158	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1452	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.763	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352872/suppl/GSM2352872_A52084400939854091415421246947280.CEL.gz	0			GSM2352872	GSM2352873_A52084400940545091515421247226803.CEL	"SUBJ.0317, SLE, baseline"	GSM2352873	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.4191780821917	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0317	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.855	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352873/suppl/GSM2352873_A52084400940545091515421247226803.CEL.gz	0	Reanalyzed by: GSM2352389		GSM2352873	GSM2352874_A52084400939920091515421247126506.CEL	"SUBJ.0317, SLE, week16"	GSM2352874	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.4191780821917	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0317	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.855	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352874/suppl/GSM2352874_A52084400939920091515421247126506.CEL.gz	0			GSM2352874	GSM2352875_A52084400940545091515421247226796.CEL	"SUBJ.0317, SLE, week52"	GSM2352875	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.4191780821917	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0317	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.855	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352875/suppl/GSM2352875_A52084400940545091515421247226796.CEL.gz	0			GSM2352875	GSM2352876_A52084400939497101415421438760474.CEL	"SUBJ.0540, SLE, baseline"	GSM2352876	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6684931506849	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0540	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.132	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352876/suppl/GSM2352876_A52084400939497101415421438760474.CEL.gz	0	Reanalyzed by: GSM2351644		GSM2352876	GSM2352877_A52084400940548091515421247226931.CEL	"SUBJ.0540, SLE, week16"	GSM2352877	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6684931506849	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0540	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.132	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352877/suppl/GSM2352877_A52084400940548091515421247226931.CEL.gz	0			GSM2352877	GSM2352878_A52084400940544091515421247226742.CEL	"SUBJ.0540, SLE, week52"	GSM2352878	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6684931506849	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0540	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.836	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.132	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352878/suppl/GSM2352878_A52084400940544091515421247226742.CEL.gz	0			GSM2352878	GSM2352879_A52084400940548091515421247226948.CEL	"SUBJ.0517, SLE, baseline"	GSM2352879	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.6465753424657	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0517	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.14	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352879/suppl/GSM2352879_A52084400940548091515421247226948.CEL.gz	0	Reanalyzed by: GSM2351802		GSM2352879	GSM2352880_A52084400940546091515421247226888.CEL	"SUBJ.0517, SLE, week16"	GSM2352880	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.6465753424657	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0517	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.14	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352880/suppl/GSM2352880_A52084400940546091515421247226888.CEL.gz	0			GSM2352880	GSM2352881_A52084400940546091515421247226867.CEL	"SUBJ.0517, SLE, week52"	GSM2352881	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.6465753424657	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0517	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.14	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352881/suppl/GSM2352881_A52084400940546091515421247226867.CEL.gz	0			GSM2352881	GSM2352882_A52084400939228091315421177045881.CEL	"SUBJ.1754, SLE, baseline"	GSM2352882	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.7568306010929	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1754	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352882/suppl/GSM2352882_A52084400939228091315421177045881.CEL.gz	0	Reanalyzed by: GSM2351501		GSM2352882	GSM2352883_A52084400939231091315421177046206.CEL	"SUBJ.1754, SLE, week16"	GSM2352883	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.7568306010929	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1754	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352883/suppl/GSM2352883_A52084400939231091315421177046206.CEL.gz	0			GSM2352883	GSM2352884_A52084400939115082215421026196679.CEL	"SUBJ.1754, SLE, week52"	GSM2352884	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.7568306010929	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1754	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352884/suppl/GSM2352884_A52084400939115082215421026196679.CEL.gz	0			GSM2352884	GSM2352885_A52084400939271081315420891403924.CEL	"SUBJ.1244, SLE, baseline"	GSM2352885	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 21.9506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1244	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352885/suppl/GSM2352885_A52084400939271081315420891403924.CEL.gz	0	Reanalyzed by: GSM2352615		GSM2352885	GSM2352886_A52084400939213081815420934611044.CEL	"SUBJ.1244, SLE, week16"	GSM2352886	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 21.9506849315068	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1244	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352886/suppl/GSM2352886_A52084400939213081815420934611044.CEL.gz	0			GSM2352886	GSM2352887_A52084400939269081315420891403757.CEL	"SUBJ.1244, SLE, week52"	GSM2352887	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 21.9506849315068	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1244	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352887/suppl/GSM2352887_A52084400939269081315420891403757.CEL.gz	0			GSM2352887	GSM2352888_A52084400939854091415421246947262.CEL	"SUBJ.0174, SLE, baseline"	GSM2352888	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7095890410959	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0174	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.08	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352888/suppl/GSM2352888_A52084400939854091415421246947262.CEL.gz	0	Reanalyzed by: GSM2351337		GSM2352888	GSM2352889_A52084400939855091415421246947316.CEL	"SUBJ.0174, SLE, week16"	GSM2352889	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7095890410959	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0174	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.08	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352889/suppl/GSM2352889_A52084400939855091415421246947316.CEL.gz	0			GSM2352889	GSM2352890_A52084400939855091415421246947337.CEL	"SUBJ.0174, SLE, week52"	GSM2352890	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.7095890410959	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0174	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.08	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352890/suppl/GSM2352890_A52084400939855091415421246947337.CEL.gz	0			GSM2352890	GSM2352891_A52084400939230091315421177046062.CEL	"SUBJ.1501, SLE, baseline"	GSM2352891	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2082191780822	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1501	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 177	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.226	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352891/suppl/GSM2352891_A52084400939230091315421177046062.CEL.gz	0	Reanalyzed by: GSM2351803		GSM2352891	GSM2352892_A52084400939844091415421247047512.CEL	"SUBJ.1501, SLE, week16"	GSM2352892	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2082191780822	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1501	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 177	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.226	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352892/suppl/GSM2352892_A52084400939844091415421247047512.CEL.gz	0			GSM2352892	GSM2352893_A52084400939231091315421177046195.CEL	"SUBJ.1501, SLE, week52"	GSM2352893	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2082191780822	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1501	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 177	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.226	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352893/suppl/GSM2352893_A52084400939231091315421177046195.CEL.gz	0			GSM2352893	GSM2352894_A52084400939920091515421247126534.CEL	"SUBJ.0484, SLE, baseline"	GSM2352894	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3424657534246	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0484	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 132	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.259	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352894/suppl/GSM2352894_A52084400939920091515421247126534.CEL.gz	0	Reanalyzed by: GSM2350953		GSM2352894	GSM2352895_A52084400940656100115421372840796.CEL	"SUBJ.0484, SLE, week16"	GSM2352895	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3424657534246	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0484	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 132	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.259	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352895/suppl/GSM2352895_A52084400940656100115421372840796.CEL.gz	0			GSM2352895	GSM2352896_A52084400940656100115421372840793.CEL	"SUBJ.0484, SLE, week52"	GSM2352896	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.3424657534246	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0484	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 132	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.259	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352896/suppl/GSM2352896_A52084400940656100115421372840793.CEL.gz	0			GSM2352896	GSM2352897_A52084400940544091515421247226756.CEL	"SUBJ.0036, SLE, baseline"	GSM2352897	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5671232876712	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0036	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.627	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.117	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352897/suppl/GSM2352897_A52084400940544091515421247226756.CEL.gz	0	Reanalyzed by: GSM2352268		GSM2352897	GSM2352898_A52084400940548091515421247226937.CEL	"SUBJ.0036, SLE, week16"	GSM2352898	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5671232876712	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0036	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.627	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.117	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352898/suppl/GSM2352898_A52084400940548091515421247226937.CEL.gz	0			GSM2352898	GSM2352899_A52084400940544091515421247226774.CEL	"SUBJ.0036, SLE, week52"	GSM2352899	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5671232876712	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0036	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.627	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.117	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352899/suppl/GSM2352899_A52084400940544091515421247226774.CEL.gz	0			GSM2352899	GSM2352900_A52084400940070100715421373649415.CEL	"SUBJ.0168, SLE, baseline"	GSM2352900	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0168	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352900/suppl/GSM2352900_A52084400940070100715421373649415.CEL.gz	0	Reanalyzed by: GSM2352112		GSM2352900	GSM2352901_A52084400940080100815421437950356.CEL	"SUBJ.0168, SLE, week52"	GSM2352901	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0168	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352901/suppl/GSM2352901_A52084400940080100815421437950356.CEL.gz	0			GSM2352901	GSM2352902_A52084400939845091415421247047585.CEL	"SUBJ.0007, SLE, baseline"	GSM2352902	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8082191780821	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0007	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.79	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.743	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352902/suppl/GSM2352902_A52084400939845091415421247047585.CEL.gz	0	Reanalyzed by: GSM2352283		GSM2352902	GSM2352903_A52084400939853091415421246947215.CEL	"SUBJ.0007, SLE, week16"	GSM2352903	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8082191780821	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0007	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.79	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.743	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352903/suppl/GSM2352903_A52084400939853091415421246947215.CEL.gz	0			GSM2352903	GSM2352904_A52084400939854091415421246947282.CEL	"SUBJ.0007, SLE, week52"	GSM2352904	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8082191780821	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0007	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.79	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.743	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352904/suppl/GSM2352904_A52084400939854091415421246947282.CEL.gz	0			GSM2352904	GSM2352905_A52084400940658100115421372840880.CEL	"SUBJ.0113, SLE, baseline"	GSM2352905	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8551912568306	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0113	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.741	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352905/suppl/GSM2352905_A52084400940658100115421372840880.CEL.gz	0	Reanalyzed by: GSM2350934		GSM2352905	GSM2352906_A52084400940658100115421372840884.CEL	"SUBJ.0113, SLE, week16"	GSM2352906	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8551912568306	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0113	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.741	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352906/suppl/GSM2352906_A52084400940658100115421372840884.CEL.gz	0			GSM2352906	GSM2352907_A52084400940657100115421372840819.CEL	"SUBJ.0113, SLE, week52"	GSM2352907	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8551912568306	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0113	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.741	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352907/suppl/GSM2352907_A52084400940657100115421372840819.CEL.gz	0			GSM2352907	GSM2352908_A52084400940549091515421247348543.CEL	"SUBJ.0889, SLE, baseline"	GSM2352908	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9672131147541	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0889	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352908/suppl/GSM2352908_A52084400940549091515421247348543.CEL.gz	0	Reanalyzed by: GSM2351818		GSM2352908	GSM2352909_A52084400940552091515421247348749.CEL	"SUBJ.0889, SLE, week16"	GSM2352909	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9672131147541	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0889	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352909/suppl/GSM2352909_A52084400940552091515421247348749.CEL.gz	0			GSM2352909	GSM2352910_A52084400940548091515421247226952.CEL	"SUBJ.0889, SLE, week52"	GSM2352910	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9672131147541	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0889	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.23	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.201	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352910/suppl/GSM2352910_A52084400940548091515421247226952.CEL.gz	0			GSM2352910	GSM2352911_A52084400940548091515421247226955.CEL	"SUBJ.1814, SLE, baseline"	GSM2352911	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.572602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1814	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.618	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352911/suppl/GSM2352911_A52084400940548091515421247226955.CEL.gz	0	Reanalyzed by: GSM2351395		GSM2352911	GSM2352912_A52084400940548091515421247226912.CEL	"SUBJ.1814, SLE, week16"	GSM2352912	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.572602739726	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1814	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.618	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352912/suppl/GSM2352912_A52084400940548091515421247226912.CEL.gz	0			GSM2352912	GSM2352913_A52084400940546091515421247226874.CEL	"SUBJ.1814, SLE, week52"	GSM2352913	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.572602739726	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1814	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.618	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352913/suppl/GSM2352913_A52084400940546091515421247226874.CEL.gz	0			GSM2352913	GSM2352914_A52084400939842091415421247047363.CEL	"SUBJ.0881, SLE, baseline"	GSM2352914	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0881	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 112	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352914/suppl/GSM2352914_A52084400939842091415421247047363.CEL.gz	0	Reanalyzed by: GSM2351851		GSM2352914	GSM2352915_A52084400939234091415421177246965.CEL	"SUBJ.0881, SLE, week16"	GSM2352915	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.6639344262295	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0881	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 112	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352915/suppl/GSM2352915_A52084400939234091415421177246965.CEL.gz	0			GSM2352915	GSM2352916_A52084400939845091415421247047573.CEL	"SUBJ.0881, SLE, week52"	GSM2352916	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.6639344262295	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0881	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 112	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352916/suppl/GSM2352916_A52084400939845091415421247047573.CEL.gz	0			GSM2352916	GSM2352917_A52084400940545091515421247226818.CEL	"SUBJ.1087, SLE, baseline"	GSM2352917	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1087	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.275	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352917/suppl/GSM2352917_A52084400940545091515421247226818.CEL.gz	0	Reanalyzed by: GSM2351649		GSM2352917	GSM2352918_A52084400940549091515421247348554.CEL	"SUBJ.1087, SLE, week16"	GSM2352918	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1087	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.275	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352918/suppl/GSM2352918_A52084400940549091515421247348554.CEL.gz	0			GSM2352918	GSM2352919_A52084400939232091415421177246846.CEL	"SUBJ.1087, SLE, week52"	GSM2352919	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1087	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.275	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352919/suppl/GSM2352919_A52084400939232091415421177246846.CEL.gz	0			GSM2352919	GSM2352920_A52084400939228091315421177045886.CEL	"SUBJ.1152, SLE, baseline"	GSM2352920	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.9945205479452	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1152	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.431	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352920/suppl/GSM2352920_A52084400939228091315421177045886.CEL.gz	0	Reanalyzed by: GSM2351977		GSM2352920	GSM2352921_A52084400939231091315421177046180.CEL	"SUBJ.1152, SLE, week16"	GSM2352921	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.9945205479452	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1152	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.431	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352921/suppl/GSM2352921_A52084400939231091315421177046180.CEL.gz	0			GSM2352921	GSM2352922_A52084400939842091415421247047387.CEL	"SUBJ.1152, SLE, week52"	GSM2352922	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 67.9945205479452	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1152	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.431	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352922/suppl/GSM2352922_A52084400939842091415421247047387.CEL.gz	0			GSM2352922	GSM2352923_A52084400939115082215421026196667.CEL	"SUBJ.0538, SLE, baseline"	GSM2352923	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.4520547945205	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0538	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352923/suppl/GSM2352923_A52084400939115082215421026196667.CEL.gz	0	Reanalyzed by: GSM2351959		GSM2352923	GSM2352924_A52084400939113082215421026196562.CEL	"SUBJ.0538, SLE, week52"	GSM2352924	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.4520547945205	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0538	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352924/suppl/GSM2352924_A52084400939113082215421026196562.CEL.gz	0			GSM2352924	GSM2352925_A52084400939115082215421026196680.CEL	"SUBJ.0532, SLE, baseline"	GSM2352925	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8934426229508	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0532	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 54	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352925/suppl/GSM2352925_A52084400939115082215421026196680.CEL.gz	0	Reanalyzed by: GSM2351336		GSM2352925	GSM2352926_A52084400939115082215421026196668.CEL	"SUBJ.0532, SLE, week16"	GSM2352926	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8934426229508	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0532	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 54	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352926/suppl/GSM2352926_A52084400939115082215421026196668.CEL.gz	0			GSM2352926	GSM2352927_A52084400939116082215421026196750.CEL	"SUBJ.0532, SLE, week52"	GSM2352927	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8934426229508	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0532	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 54	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.128	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352927/suppl/GSM2352927_A52084400939116082215421026196750.CEL.gz	0			GSM2352927	GSM2352928_A52084400939113082215421026196552.CEL	"SUBJ.0301, SLE, baseline"	GSM2352928	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.7841530054644	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0301	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.633	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352928/suppl/GSM2352928_A52084400939113082215421026196552.CEL.gz	0	Reanalyzed by: GSM2351265		GSM2352928	GSM2352929_A52084400939113082215421026196576.CEL	"SUBJ.0301, SLE, week16"	GSM2352929	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.7841530054644	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0301	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.633	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352929/suppl/GSM2352929_A52084400939113082215421026196576.CEL.gz	0			GSM2352929	GSM2352930_A52084400939114082215421026196630.CEL	"SUBJ.0301, SLE, week52"	GSM2352930	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.7841530054644	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0301	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.633	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.194	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352930/suppl/GSM2352930_A52084400939114082215421026196630.CEL.gz	0			GSM2352930	GSM2352931_A52084400939852091415421246947149.CEL	"SUBJ.0216, SLE, baseline"	GSM2352931	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.8907103825136	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0216	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352931/suppl/GSM2352931_A52084400939852091415421246947149.CEL.gz	0	Reanalyzed by: GSM2352560		GSM2352931	GSM2352932_A52084400939852091415421246947166.CEL	"SUBJ.0216, SLE, week16"	GSM2352932	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.8907103825136	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0216	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352932/suppl/GSM2352932_A52084400939852091415421246947166.CEL.gz	0			GSM2352932	GSM2352933_A52084400939852091415421246947131.CEL	"SUBJ.0216, SLE, week52"	GSM2352933	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.8907103825136	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0216	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352933/suppl/GSM2352933_A52084400939852091415421246947131.CEL.gz	0			GSM2352933	GSM2352934_A52084400939921091515421247126581.CEL	"SUBJ.1332, SLE, baseline"	GSM2352934	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1332	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352934/suppl/GSM2352934_A52084400939921091515421247126581.CEL.gz	0	Reanalyzed by: GSM2351131		GSM2352934	GSM2352935_A52084400939920091515421247126517.CEL	"SUBJ.1332, SLE, week16"	GSM2352935	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1332	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352935/suppl/GSM2352935_A52084400939920091515421247126517.CEL.gz	0			GSM2352935	GSM2352936_A52084400939472101415421438760285.CEL	"SUBJ.1332, SLE, week52"	GSM2352936	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1332	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352936/suppl/GSM2352936_A52084400939472101415421438760285.CEL.gz	0			GSM2352936	GSM2352937_A52084400939115082215421026196671.CEL	"SUBJ.1199, SLE, baseline"	GSM2352937	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1199	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.611	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.07	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352937/suppl/GSM2352937_A52084400939115082215421026196671.CEL.gz	0	Reanalyzed by: GSM2352311		GSM2352937	GSM2352938_A52084400939212081815420934610995.CEL	"SUBJ.1199, SLE, week16"	GSM2352938	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3616438356164	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1199	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.611	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.07	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352938/suppl/GSM2352938_A52084400939212081815420934610995.CEL.gz	0			GSM2352938	GSM2352939_A52084400939212081815420934610994.CEL	"SUBJ.1199, SLE, week52"	GSM2352939	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3616438356164	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1199	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.611	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.07	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352939/suppl/GSM2352939_A52084400939212081815420934610994.CEL.gz	0			GSM2352939	GSM2352940_A52084400939921091515421247126587.CEL	"SUBJ.0002, SLE, baseline"	GSM2352940	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.545205479452	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0002	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.931	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352940/suppl/GSM2352940_A52084400939921091515421247126587.CEL.gz	0	Reanalyzed by: GSM2351070		GSM2352940	GSM2352941_A52084400939921091515421247126557.CEL	"SUBJ.0002, SLE, week16"	GSM2352941	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.545205479452	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0002	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.931	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352941/suppl/GSM2352941_A52084400939921091515421247126557.CEL.gz	0			GSM2352941	GSM2352942_A52084400939847091515421247126701.CEL	"SUBJ.0002, SLE, week52"	GSM2352942	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.545205479452	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0002	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.931	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352942/suppl/GSM2352942_A52084400939847091515421247126701.CEL.gz	0			GSM2352942	GSM2352943_A52084400939234091415421177246985.CEL	"SUBJ.0541, SLE, week16"	GSM2352943	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.9780821917808	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0541	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 71	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.86	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.326	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352943/suppl/GSM2352943_A52084400939234091415421177246985.CEL.gz	0			GSM2352943	GSM2352944_A52084400940549091515421247348564.CEL	"SUBJ.0541, SLE, week52"	GSM2352944	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.9780821917808	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0541	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 71	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.86	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.326	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352944/suppl/GSM2352944_A52084400940549091515421247348564.CEL.gz	0			GSM2352944	GSM2352945_A52084400940546091515421247226891.CEL	"SUBJ.1738, SLE, baseline"	GSM2352945	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.358904109589	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1738	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.909	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352945/suppl/GSM2352945_A52084400940546091515421247226891.CEL.gz	0	Reanalyzed by: GSM2351700		GSM2352945	GSM2352946_A52084400939921091515421247126551.CEL	"SUBJ.1738, SLE, week16"	GSM2352946	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.358904109589	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1738	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.909	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352946/suppl/GSM2352946_A52084400939921091515421247126551.CEL.gz	0			GSM2352946	GSM2352947_A52084400940544091515421247226749.CEL	"SUBJ.1738, SLE, week52"	GSM2352947	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.358904109589	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1738	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.909	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352947/suppl/GSM2352947_A52084400940544091515421247226749.CEL.gz	0			GSM2352947	GSM2352948_A52084400939920091515421247126522.CEL	"SUBJ.1029, SLE, baseline"	GSM2352948	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.531506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1029	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 44	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352948/suppl/GSM2352948_A52084400939920091515421247126522.CEL.gz	0	Reanalyzed by: GSM2351527		GSM2352948	GSM2352949_A52084400940659100115421372840967.CEL	"SUBJ.1029, SLE, week16"	GSM2352949	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.531506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1029	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 44	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352949/suppl/GSM2352949_A52084400940659100115421372840967.CEL.gz	0			GSM2352949	GSM2352950_A52084400940656100115421372840754.CEL	"SUBJ.1029, SLE, week52"	GSM2352950	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.531506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1029	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 44	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.52	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352950/suppl/GSM2352950_A52084400940656100115421372840754.CEL.gz	0			GSM2352950	GSM2352951_A52084400939235091415421177247064.CEL	"SUBJ.0177, SLE, baseline"	GSM2352951	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7643835616438	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0177	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.65	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352951/suppl/GSM2352951_A52084400939235091415421177247064.CEL.gz	0	Reanalyzed by: GSM2351908		GSM2352951	GSM2352952_A52084400940656100115421372840779.CEL	"SUBJ.0177, SLE, week16"	GSM2352952	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7643835616438	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0177	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.65	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352952/suppl/GSM2352952_A52084400940656100115421372840779.CEL.gz	0			GSM2352952	GSM2352953_A52084400939846091515421247126637.CEL	"SUBJ.0177, SLE, week52"	GSM2352953	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.7643835616438	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0177	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.65	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352953/suppl/GSM2352953_A52084400939846091515421247126637.CEL.gz	0			GSM2352953	GSM2352954_A52084400939115082215421026196704.CEL	"SUBJ.0526, SLE, baseline"	GSM2352954	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7568306010929	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0526	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.991	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352954/suppl/GSM2352954_A52084400939115082215421026196704.CEL.gz	0	Reanalyzed by: GSM2351906		GSM2352954	GSM2352955_A52084400939114082215421026196620.CEL	"SUBJ.0526, SLE, week16"	GSM2352955	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7568306010929	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0526	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.991	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352955/suppl/GSM2352955_A52084400939114082215421026196620.CEL.gz	0			GSM2352955	GSM2352956_A52084400939116082215421026196745.CEL	"SUBJ.0526, SLE, week52"	GSM2352956	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7568306010929	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0526	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.991	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352956/suppl/GSM2352956_A52084400939116082215421026196745.CEL.gz	0			GSM2352956	GSM2352957_A52084400939855091415421246947304.CEL	"SUBJ.0505, SLE, baseline"	GSM2352957	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.1479452054794	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0505	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.297	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352957/suppl/GSM2352957_A52084400939855091415421246947304.CEL.gz	0	Reanalyzed by: GSM2351558		GSM2352957	GSM2352958_A52084400939852091415421246947125.CEL	"SUBJ.0505, SLE, week16"	GSM2352958	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.1479452054794	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0505	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.297	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352958/suppl/GSM2352958_A52084400939852091415421246947125.CEL.gz	0			GSM2352958	GSM2352959_A52084400939845091415421247047566.CEL	"SUBJ.0505, SLE, week52"	GSM2352959	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.1479452054794	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0505	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.297	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352959/suppl/GSM2352959_A52084400939845091415421247047566.CEL.gz	0			GSM2352959	GSM2352960_A52084400940067100715421373649254.CEL	"SUBJ.0182, SLE, baseline"	GSM2352960	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.7479452054794	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0182	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.57	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.357	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352960/suppl/GSM2352960_A52084400940067100715421373649254.CEL.gz	0	Reanalyzed by: GSM2351836		GSM2352960	GSM2352961_A52084400940069100715421373649355.CEL	"SUBJ.0182, SLE, week16"	GSM2352961	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.7479452054794	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0182	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.57	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.357	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352961/suppl/GSM2352961_A52084400940069100715421373649355.CEL.gz	0			GSM2352961	GSM2352962_A52084400940069100715421373649358.CEL	"SUBJ.0182, SLE, week52"	GSM2352962	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.7479452054794	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0182	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.57	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.357	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352962/suppl/GSM2352962_A52084400940069100715421373649358.CEL.gz	0			GSM2352962	GSM2352963_A52084400939234091415421177246962.CEL	"SUBJ.1062, SLE, baseline"	GSM2352963	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9125683060109	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1062	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.803	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.209	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352963/suppl/GSM2352963_A52084400939234091415421177246962.CEL.gz	0	Reanalyzed by: GSM2352068		GSM2352963	GSM2352964_A52084400940552091515421247348718.CEL	"SUBJ.1062, SLE, week16"	GSM2352964	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9125683060109	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1062	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.803	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.209	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352964/suppl/GSM2352964_A52084400940552091515421247348718.CEL.gz	0			GSM2352964	GSM2352965_A52084400939232091415421177246862.CEL	"SUBJ.1062, SLE, week52"	GSM2352965	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9125683060109	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1062	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.803	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.209	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352965/suppl/GSM2352965_A52084400939232091415421177246862.CEL.gz	0			GSM2352965	GSM2352966_A52084400939212081815420934610991.CEL	"SUBJ.0186, SLE, baseline"	GSM2352966	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6136986301369	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0186	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.06	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352966/suppl/GSM2352966_A52084400939212081815420934610991.CEL.gz	0	Reanalyzed by: GSM2351482		GSM2352966	GSM2352967_A52084400939213081815420934611052.CEL	"SUBJ.0186, SLE, week16"	GSM2352967	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6136986301369	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0186	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.06	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352967/suppl/GSM2352967_A52084400939213081815420934611052.CEL.gz	0			GSM2352967	GSM2352968_A52084400939215081815420934611148.CEL	"SUBJ.0186, SLE, week52"	GSM2352968	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 71.6136986301369	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0186	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.06	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352968/suppl/GSM2352968_A52084400939215081815420934611148.CEL.gz	0			GSM2352968	GSM2352969_A52084400939212081815420934610980.CEL	"SUBJ.1221, SLE, baseline"	GSM2352969	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8219178082191	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1221	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352969/suppl/GSM2352969_A52084400939212081815420934610980.CEL.gz	0	Reanalyzed by: GSM2352336		GSM2352969	GSM2352970_A52084400939116082215421026196741.CEL	"SUBJ.1221, SLE, week16"	GSM2352970	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8219178082191	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1221	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352970/suppl/GSM2352970_A52084400939116082215421026196741.CEL.gz	0			GSM2352970	GSM2352971_A52084400939115082215421026196661.CEL	"SUBJ.1221, SLE, week52"	GSM2352971	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8219178082191	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1221	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352971/suppl/GSM2352971_A52084400939115082215421026196661.CEL.gz	0			GSM2352971	GSM2352972_A52084400939920091515421247126511.CEL	"SUBJ.1778, SLE, baseline"	GSM2352972	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7841530054644	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1778	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.3	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.393	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352972/suppl/GSM2352972_A52084400939920091515421247126511.CEL.gz	0	Reanalyzed by: GSM2351603		GSM2352972	GSM2352973_A52084400940659100115421372840945.CEL	"SUBJ.1778, SLE, week16"	GSM2352973	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7841530054644	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1778	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.3	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.393	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352973/suppl/GSM2352973_A52084400940659100115421372840945.CEL.gz	0			GSM2352973	GSM2352974_A52084400939846091515421247126614.CEL	"SUBJ.1778, SLE, week52"	GSM2352974	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.7841530054644	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1778	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.3	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.393	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352974/suppl/GSM2352974_A52084400939846091515421247126614.CEL.gz	0			GSM2352974	GSM2352975_A52084400939232091415421177246854.CEL	"SUBJ.0049, SLE, baseline"	GSM2352975	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.7978142076502	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0049	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.473	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352975/suppl/GSM2352975_A52084400939232091415421177246854.CEL.gz	0	Reanalyzed by: GSM2351811		GSM2352975	GSM2352976_A52084400939232091415421177246843.CEL	"SUBJ.0049, SLE, week16"	GSM2352976	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.7978142076502	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0049	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.473	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352976/suppl/GSM2352976_A52084400939232091415421177246843.CEL.gz	0			GSM2352976	GSM2352977_A52084400939235091415421177247065.CEL	"SUBJ.0049, SLE, week52"	GSM2352977	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.7978142076502	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0049	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.473	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352977/suppl/GSM2352977_A52084400939235091415421177247065.CEL.gz	0			GSM2352977	GSM2352978_A52084400939853091415421246947217.CEL	"SUBJ.1248, SLE, baseline"	GSM2352978	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8524590163934	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1248	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352978/suppl/GSM2352978_A52084400939853091415421246947217.CEL.gz	0	Reanalyzed by: GSM2351852		GSM2352978	GSM2352979_A52084400939855091415421246947303.CEL	"SUBJ.1248, SLE, week16"	GSM2352979	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8524590163934	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1248	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352979/suppl/GSM2352979_A52084400939855091415421246947303.CEL.gz	0			GSM2352979	GSM2352980_A52084400939854091415421246947269.CEL	"SUBJ.1248, SLE, week52"	GSM2352980	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8524590163934	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1248	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352980/suppl/GSM2352980_A52084400939854091415421246947269.CEL.gz	0			GSM2352980	GSM2352981_A52084400939496101415421438760405.CEL	"SUBJ.0874, SLE, baseline"	GSM2352981	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0874	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352981/suppl/GSM2352981_A52084400939496101415421438760405.CEL.gz	0	Reanalyzed by: GSM2351308		GSM2352981	GSM2352982_A52084400939234091415421177246964.CEL	"SUBJ.0874, SLE, week16"	GSM2352982	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2767123287671	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0874	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352982/suppl/GSM2352982_A52084400939234091415421177246964.CEL.gz	0			GSM2352982	GSM2352983_A52084400939234091415421177246971.CEL	"SUBJ.0874, SLE, week52"	GSM2352983	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2767123287671	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0874	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352983/suppl/GSM2352983_A52084400939234091415421177246971.CEL.gz	0			GSM2352983	GSM2352984_A52084400940546091515421247226855.CEL	"SUBJ.1257, SLE, baseline"	GSM2352984	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 63.8770491803278	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1257	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352984/suppl/GSM2352984_A52084400940546091515421247226855.CEL.gz	0	Reanalyzed by: GSM2351179		GSM2352984	GSM2352985_A52084400940548091515421247226950.CEL	"SUBJ.1257, SLE, week16"	GSM2352985	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 63.8770491803278	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1257	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352985/suppl/GSM2352985_A52084400940548091515421247226950.CEL.gz	0			GSM2352985	GSM2352986_A52084400940546091515421247226872.CEL	"SUBJ.1257, SLE, week52"	GSM2352986	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 63.8770491803278	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1257	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352986/suppl/GSM2352986_A52084400940546091515421247226872.CEL.gz	0			GSM2352986	GSM2352987_A52084400939114082215421026196606.CEL	"SUBJ.0158, SLE, baseline"	GSM2352987	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9397260273972	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0158	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352987/suppl/GSM2352987_A52084400939114082215421026196606.CEL.gz	0	Reanalyzed by: GSM2351547		GSM2352987	GSM2352988_A52084400939113082215421026196554.CEL	"SUBJ.0158, SLE, week16"	GSM2352988	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9397260273972	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0158	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352988/suppl/GSM2352988_A52084400939113082215421026196554.CEL.gz	0			GSM2352988	GSM2352989_A52084400939113082215421026196578.CEL	"SUBJ.0158, SLE, week52"	GSM2352989	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9397260273972	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0158	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.32	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352989/suppl/GSM2352989_A52084400939113082215421026196578.CEL.gz	0			GSM2352989	GSM2352990_A52084400940067100715421373649227.CEL	"SUBJ.1496, SLE, baseline"	GSM2352990	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.7185792349726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1496	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 125	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.902	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352990/suppl/GSM2352990_A52084400940067100715421373649227.CEL.gz	0	Reanalyzed by: GSM2352396		GSM2352990	GSM2352991_A52084400940080100815421437950360.CEL	"SUBJ.1496, SLE, week16"	GSM2352991	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.7185792349726	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1496	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 125	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.902	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352991/suppl/GSM2352991_A52084400940080100815421437950360.CEL.gz	0			GSM2352991	GSM2352992_A52084400940082100815421437950462.CEL	"SUBJ.1496, SLE, week52"	GSM2352992	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.7185792349726	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1496	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 125	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.902	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.101	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352992/suppl/GSM2352992_A52084400940082100815421437950462.CEL.gz	0			GSM2352992	GSM2352993_A52084400939213081815420934611026.CEL	"SUBJ.1135, SLE, baseline"	GSM2352993	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0438356164383	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1135	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.76	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.067	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352993/suppl/GSM2352993_A52084400939213081815420934611026.CEL.gz	0	Reanalyzed by: GSM2350933		GSM2352993	GSM2352994_A52084400939213081815420934611033.CEL	"SUBJ.1135, SLE, week16"	GSM2352994	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0438356164383	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1135	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.76	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.067	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352994/suppl/GSM2352994_A52084400939213081815420934611033.CEL.gz	0			GSM2352994	GSM2352995_A52084400939214081815420934611101.CEL	"SUBJ.1135, SLE, week52"	GSM2352995	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0438356164383	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1135	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.76	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.067	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352995/suppl/GSM2352995_A52084400939214081815420934611101.CEL.gz	0			GSM2352995	GSM2352996_A52084400939847091515421247126670.CEL	"SUBJ.1639, SLE, baseline"	GSM2352996	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.8931506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1639	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 51	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352996/suppl/GSM2352996_A52084400939847091515421247126670.CEL.gz	0	Reanalyzed by: GSM2351447		GSM2352996	GSM2352997_A52084400939920091515421247126524.CEL	"SUBJ.1639, SLE, week16"	GSM2352997	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.8931506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1639	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 51	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352997/suppl/GSM2352997_A52084400939920091515421247126524.CEL.gz	0			GSM2352997	GSM2352998_A52084400939846091515421247126649.CEL	"SUBJ.1639, SLE, week52"	GSM2352998	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.8931506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1639	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 51	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352998/suppl/GSM2352998_A52084400939846091515421247126649.CEL.gz	0			GSM2352998	GSM2352999_A52084400940548091515421247226949.CEL	"SUBJ.1459, SLE, baseline"	GSM2352999	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.6602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1459	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.287	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2352nnn/GSM2352999/suppl/GSM2352999_A52084400940548091515421247226949.CEL.gz	0	Reanalyzed by: GSM2351090		GSM2352999	GSM2353000_A52084400940548091515421247226936.CEL	"SUBJ.1459, SLE, week16"	GSM2353000	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.6602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1459	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.287	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353000/suppl/GSM2353000_A52084400940548091515421247226936.CEL.gz	0			GSM2353000	GSM2353001_A52084400940548091515421247226923.CEL	"SUBJ.1459, SLE, week52"	GSM2353001	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.6602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1459	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.287	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353001/suppl/GSM2353001_A52084400940548091515421247226923.CEL.gz	0			GSM2353001	GSM2353002_A52084400939233091415421177246902.CEL	"SUBJ.0127, SLE, baseline"	GSM2353002	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.7814207650273	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0127	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.796	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353002/suppl/GSM2353002_A52084400939233091415421177246902.CEL.gz	0	Reanalyzed by: GSM2351435		GSM2353002	GSM2353003_A52084400939234091415421177246963.CEL	"SUBJ.0127, SLE, week16"	GSM2353003	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.7814207650273	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0127	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.796	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353003/suppl/GSM2353003_A52084400939234091415421177246963.CEL.gz	0			GSM2353003	GSM2353004_A52084400939235091415421177247090.CEL	"SUBJ.0127, SLE, week52"	GSM2353004	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.7814207650273	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0127	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.796	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353004/suppl/GSM2353004_A52084400939235091415421177247090.CEL.gz	0			GSM2353004	GSM2353005_A52084400940080100815421437950352.CEL	"SUBJ.1105, SLE, baseline"	GSM2353005	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9453551912568	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1105	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.589	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353005/suppl/GSM2353005_A52084400940080100815421437950352.CEL.gz	0	Reanalyzed by: GSM2351990		GSM2353005	GSM2353006_A52084400940082100815421437950449.CEL	"SUBJ.1105, SLE, week16"	GSM2353006	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9453551912568	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1105	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.589	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353006/suppl/GSM2353006_A52084400940082100815421437950449.CEL.gz	0			GSM2353006	GSM2353007_A52084400940082100815421437950463.CEL	"SUBJ.1105, SLE, week52"	GSM2353007	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9453551912568	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1105	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 110	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.589	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353007/suppl/GSM2353007_A52084400940082100815421437950463.CEL.gz	0			GSM2353007	GSM2353008_A52084400939115082215421026196700.CEL	"SUBJ.1107, SLE, baseline"	GSM2353008	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.8054794520548	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1107	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.208	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353008/suppl/GSM2353008_A52084400939115082215421026196700.CEL.gz	0	Reanalyzed by: GSM2352407		GSM2353008	GSM2353009_A52084400939907082115420971516275.CEL	"SUBJ.1107, SLE, week16"	GSM2353009	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.8054794520548	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1107	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.208	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353009/suppl/GSM2353009_A52084400939907082115420971516275.CEL.gz	0			GSM2353009	GSM2353010_A52084400939115082215421026196663.CEL	"SUBJ.1107, SLE, week52"	GSM2353010	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.8054794520548	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1107	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.208	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353010/suppl/GSM2353010_A52084400939115082215421026196663.CEL.gz	0			GSM2353010	GSM2353011_A52084400939113082215421026196551.CEL	"SUBJ.0592, SLE, baseline"	GSM2353011	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0592	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353011/suppl/GSM2353011_A52084400939113082215421026196551.CEL.gz	0	Reanalyzed by: GSM2352361		GSM2353011	GSM2353012_A52084400939116082215421026196721.CEL	"SUBJ.0592, SLE, week16"	GSM2353012	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5506849315068	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0592	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353012/suppl/GSM2353012_A52084400939116082215421026196721.CEL.gz	0			GSM2353012	GSM2353013_A52084400939115082215421026196696.CEL	"SUBJ.0592, SLE, week52"	GSM2353013	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5506849315068	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0592	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353013/suppl/GSM2353013_A52084400939115082215421026196696.CEL.gz	0			GSM2353013	GSM2353014_A52084400939228091315421177045864.CEL	"SUBJ.1701, SLE, baseline"	GSM2353014	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6830601092896	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1701	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353014/suppl/GSM2353014_A52084400939228091315421177045864.CEL.gz	0	Reanalyzed by: GSM2351348		GSM2353014	GSM2353015_A52084400939842091415421247047375.CEL	"SUBJ.1701, SLE, week16"	GSM2353015	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6830601092896	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1701	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353015/suppl/GSM2353015_A52084400939842091415421247047375.CEL.gz	0			GSM2353015	GSM2353016_A52084400939844091415421247047516.CEL	"SUBJ.1701, SLE, week52"	GSM2353016	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.6830601092896	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1701	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353016/suppl/GSM2353016_A52084400939844091415421247047516.CEL.gz	0			GSM2353016	GSM2353017_A52084400940548091515421247226915.CEL	"SUBJ.1334, SLE, baseline"	GSM2353017	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8551912568306	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1334	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353017/suppl/GSM2353017_A52084400940548091515421247226915.CEL.gz	0	Reanalyzed by: GSM2351169		GSM2353017	GSM2353018_A52084400940546091515421247226894.CEL	"SUBJ.1334, SLE, week16"	GSM2353018	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8551912568306	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1334	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353018/suppl/GSM2353018_A52084400940546091515421247226894.CEL.gz	0			GSM2353018	GSM2353019_A52084400940545091515421247226825.CEL	"SUBJ.1334, SLE, week52"	GSM2353019	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.8551912568306	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1334	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353019/suppl/GSM2353019_A52084400940545091515421247226825.CEL.gz	0			GSM2353019	GSM2353020_A52084400939233091415421177246900.CEL	"SUBJ.0025, SLE, baseline"	GSM2353020	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7923497267759	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0025	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.801	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.078	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353020/suppl/GSM2353020_A52084400939233091415421177246900.CEL.gz	0	Reanalyzed by: GSM2352072		GSM2353020	GSM2353021_A52084400939472101415421438760271.CEL	"SUBJ.0025, SLE, week16"	GSM2353021	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7923497267759	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0025	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.801	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.078	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353021/suppl/GSM2353021_A52084400939472101415421438760271.CEL.gz	0			GSM2353021	GSM2353022_A52084400939235091415421177247089.CEL	"SUBJ.0025, SLE, week52"	GSM2353022	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7923497267759	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0025	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.801	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.078	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353022/suppl/GSM2353022_A52084400939235091415421177247089.CEL.gz	0			GSM2353022	GSM2353023_A52084400939212081815420934610958.CEL	"SUBJ.1782, SLE, baseline"	GSM2353023	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7213114754098	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1782	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.728	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353023/suppl/GSM2353023_A52084400939212081815420934610958.CEL.gz	0	Reanalyzed by: GSM2351211		GSM2353023	GSM2353024_A52084400939215081815420934611170.CEL	"SUBJ.1782, SLE, week16"	GSM2353024	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7213114754098	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1782	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.728	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353024/suppl/GSM2353024_A52084400939215081815420934611170.CEL.gz	0			GSM2353024	GSM2353025_A52084400939496101415421438760414.CEL	"SUBJ.1782, SLE, week52"	GSM2353025	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7213114754098	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1782	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.728	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.062	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353025/suppl/GSM2353025_A52084400939496101415421438760414.CEL.gz	0			GSM2353025	GSM2353026_A52084400940658100115421372840898.CEL	"SUBJ.1397, SLE, baseline"	GSM2353026	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8547945205479	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1397	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.71	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353026/suppl/GSM2353026_A52084400940658100115421372840898.CEL.gz	0	Reanalyzed by: GSM2351290		GSM2353026	GSM2353027_A52084400940658100115421372840912.CEL	"SUBJ.1397, SLE, week16"	GSM2353027	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8547945205479	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1397	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.71	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353027/suppl/GSM2353027_A52084400940658100115421372840912.CEL.gz	0			GSM2353027	GSM2353028_A52084400940656100115421372840770.CEL	"SUBJ.1397, SLE, week52"	GSM2353028	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8547945205479	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1397	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.71	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353028/suppl/GSM2353028_A52084400940656100115421372840770.CEL.gz	0			GSM2353028	GSM2353029_A52084400939212081815420934610976.CEL	"SUBJ.0972, SLE, baseline"	GSM2353029	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.3616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0972	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.739	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353029/suppl/GSM2353029_A52084400939212081815420934610976.CEL.gz	0	Reanalyzed by: GSM2351277		GSM2353029	GSM2353030_A52084400939213081815420934611028.CEL	"SUBJ.0972, SLE, week16"	GSM2353030	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.3616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0972	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.739	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353030/suppl/GSM2353030_A52084400939213081815420934611028.CEL.gz	0			GSM2353030	GSM2353031_A52084400939212081815420934610964.CEL	"SUBJ.0972, SLE, week52"	GSM2353031	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.3616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0972	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.739	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.086	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353031/suppl/GSM2353031_A52084400939212081815420934610964.CEL.gz	0			GSM2353031	GSM2353032_A52084400939496101415421438775736.CEL	"SUBJ.0973, SLE, baseline"	GSM2353032	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.2986301369863	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0973	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.947	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353032/suppl/GSM2353032_A52084400939496101415421438775736.CEL.gz	0	Reanalyzed by: GSM2352337		GSM2353032	GSM2353033_A52084400939233091415421177246925.CEL	"SUBJ.0973, SLE, week16"	GSM2353033	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.2986301369863	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0973	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.947	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353033/suppl/GSM2353033_A52084400939233091415421177246925.CEL.gz	0			GSM2353033	GSM2353034_A52084400940657100115421372840861.CEL	"SUBJ.0973, SLE, week52"	GSM2353034	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.2986301369863	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0973	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.947	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353034/suppl/GSM2353034_A52084400940657100115421372840861.CEL.gz	0			GSM2353034	GSM2353035_A52084400940550091515421247348590.CEL	"SUBJ.1139, SLE, baseline"	GSM2353035	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.5150684931507	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1139	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.366	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353035/suppl/GSM2353035_A52084400940550091515421247348590.CEL.gz	0	Reanalyzed by: GSM2351762		GSM2353035	GSM2353036_A52084400940551091515421247348651.CEL	"SUBJ.1139, SLE, week16"	GSM2353036	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.5150684931507	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1139	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.366	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353036/suppl/GSM2353036_A52084400940551091515421247348651.CEL.gz	0			GSM2353036	GSM2353037_A52084400940544091515421247226752.CEL	"SUBJ.1139, SLE, week52"	GSM2353037	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.5150684931507	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1139	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.366	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353037/suppl/GSM2353037_A52084400940544091515421247226752.CEL.gz	0			GSM2353037	GSM2353038_A52084400939855091415421246947329.CEL	"SUBJ.1480, SLE, baseline"	GSM2353038	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6520547945205	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1480	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 64	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.166	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353038/suppl/GSM2353038_A52084400939855091415421246947329.CEL.gz	0	Reanalyzed by: GSM2351172		GSM2353038	GSM2353039_A52084400939855091415421246947310.CEL	"SUBJ.1480, SLE, week16"	GSM2353039	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6520547945205	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1480	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 64	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.166	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353039/suppl/GSM2353039_A52084400939855091415421246947310.CEL.gz	0			GSM2353039	GSM2353040_A52084400939232091415421177246858.CEL	"SUBJ.1480, SLE, week52"	GSM2353040	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.6520547945205	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1480	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 64	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.2	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.166	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353040/suppl/GSM2353040_A52084400939232091415421177246858.CEL.gz	0			GSM2353040	GSM2353041_A52084400940658100115421372840911.CEL	"SUBJ.0801, SLE, baseline"	GSM2353041	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9071038251366	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0801	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.701	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353041/suppl/GSM2353041_A52084400940658100115421372840911.CEL.gz	0	Reanalyzed by: GSM2352306		GSM2353041	GSM2353042_A52084400940659100115421372840950.CEL	"SUBJ.0801, SLE, week16"	GSM2353042	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9071038251366	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0801	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.701	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353042/suppl/GSM2353042_A52084400940659100115421372840950.CEL.gz	0			GSM2353042	GSM2353043_A52084400940657100115421372840835.CEL	"SUBJ.0801, SLE, week52"	GSM2353043	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9071038251366	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0801	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.701	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353043/suppl/GSM2353043_A52084400940657100115421372840835.CEL.gz	0			GSM2353043	GSM2353044_A52084400939847091515421247126702.CEL	"SUBJ.1206, SLE, baseline"	GSM2353044	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.0273972602739	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1206	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.777	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353044/suppl/GSM2353044_A52084400939847091515421247126702.CEL.gz	0	Reanalyzed by: GSM2351544		GSM2353044	GSM2353045_A52084400939846091515421247126616.CEL	"SUBJ.1206, SLE, week16"	GSM2353045	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.0273972602739	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1206	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.777	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353045/suppl/GSM2353045_A52084400939846091515421247126616.CEL.gz	0			GSM2353045	GSM2353046_A52084400939846091515421247126633.CEL	"SUBJ.1206, SLE, week52"	GSM2353046	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.0273972602739	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1206	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 254	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.777	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353046/suppl/GSM2353046_A52084400939846091515421247126633.CEL.gz	0			GSM2353046	GSM2353047_A52084400940658100115421372840904.CEL	"SUBJ.1655, SLE, baseline"	GSM2353047	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8770491803278	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1655	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.842	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353047/suppl/GSM2353047_A52084400940658100115421372840904.CEL.gz	0	Reanalyzed by: GSM2352033		GSM2353047	GSM2353048_A52084400940658100115421372840897.CEL	"SUBJ.1655, SLE, week16"	GSM2353048	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8770491803278	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1655	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.842	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353048/suppl/GSM2353048_A52084400940658100115421372840897.CEL.gz	0			GSM2353048	GSM2353049_A52084400940658100115421372840906.CEL	"SUBJ.1655, SLE, week52"	GSM2353049	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8770491803278	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1655	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.842	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353049/suppl/GSM2353049_A52084400940658100115421372840906.CEL.gz	0			GSM2353049	GSM2353050_A52084400939114082215421026196608.CEL	"SUBJ.0141, SLE, baseline"	GSM2353050	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.9672131147541	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0141	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 130	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353050/suppl/GSM2353050_A52084400939114082215421026196608.CEL.gz	0	Reanalyzed by: GSM2351379		GSM2353050	GSM2353051_A52084400939113082215421026196563.CEL	"SUBJ.0141, SLE, week16"	GSM2353051	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.9672131147541	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0141	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 130	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353051/suppl/GSM2353051_A52084400939113082215421026196563.CEL.gz	0			GSM2353051	GSM2353052_A52084400939114082215421026196628.CEL	"SUBJ.0141, SLE, week52"	GSM2353052	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.9672131147541	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0141	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 130	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353052/suppl/GSM2353052_A52084400939114082215421026196628.CEL.gz	0			GSM2353052	GSM2353053_A52084400939115082215421026196692.CEL	"SUBJ.1085, SLE, baseline"	GSM2353053	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.572602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1085	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353053/suppl/GSM2353053_A52084400939115082215421026196692.CEL.gz	0	Reanalyzed by: GSM2352180		GSM2353053	GSM2353054_A52084400939114082215421026196626.CEL	"SUBJ.1085, SLE, week16"	GSM2353054	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.572602739726	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1085	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353054/suppl/GSM2353054_A52084400939114082215421026196626.CEL.gz	0			GSM2353054	GSM2353055_A52084400939115082215421026196710.CEL	"SUBJ.1085, SLE, week52"	GSM2353055	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.572602739726	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1085	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.31	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353055/suppl/GSM2353055_A52084400939115082215421026196710.CEL.gz	0			GSM2353055	GSM2353056_A52084400939847091515421247126698.CEL	"SUBJ.0104, SLE, baseline"	GSM2353056	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.9397260273972	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0104	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353056/suppl/GSM2353056_A52084400939847091515421247126698.CEL.gz	0	Reanalyzed by: GSM2351812		GSM2353056	GSM2353057_A52084400939847091515421247126669.CEL	"SUBJ.0104, SLE, week16"	GSM2353057	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.9397260273972	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0104	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353057/suppl/GSM2353057_A52084400939847091515421247126669.CEL.gz	0			GSM2353057	GSM2353058_A52084400939920091515421247126519.CEL	"SUBJ.0104, SLE, week52"	GSM2353058	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.9397260273972	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0104	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353058/suppl/GSM2353058_A52084400939920091515421247126519.CEL.gz	0			GSM2353058	GSM2353059_A52084400940550091515421247348620.CEL	"SUBJ.1562, SLE, baseline"	GSM2353059	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.4383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1562	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353059/suppl/GSM2353059_A52084400940550091515421247348620.CEL.gz	0	Reanalyzed by: GSM2352265		GSM2353059	GSM2353060_A52084400940550091515421247348592.CEL	"SUBJ.1562, SLE, week16"	GSM2353060	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.4383561643835	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1562	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353060/suppl/GSM2353060_A52084400940550091515421247348592.CEL.gz	0			GSM2353060	GSM2353061_A52084400939270081315420891403843.CEL	"SUBJ.1265, SLE, baseline"	GSM2353061	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5260273972602	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1265	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 60	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.532	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353061/suppl/GSM2353061_A52084400939270081315420891403843.CEL.gz	0	Reanalyzed by: GSM2351800		GSM2353061	GSM2353062_A52084400939212081815420934610990.CEL	"SUBJ.1265, SLE, week16"	GSM2353062	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5260273972602	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1265	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 60	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.532	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353062/suppl/GSM2353062_A52084400939212081815420934610990.CEL.gz	0			GSM2353062	GSM2353063_A52084400939271081315420891403893.CEL	"SUBJ.1265, SLE, week52"	GSM2353063	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5260273972602	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1265	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 60	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.532	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353063/suppl/GSM2353063_A52084400939271081315420891403893.CEL.gz	0			GSM2353063	GSM2353064_A52084400939235091415421177247085.CEL	"SUBJ.1009, SLE, baseline"	GSM2353064	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9890410958904	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1009	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.195	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353064/suppl/GSM2353064_A52084400939235091415421177247085.CEL.gz	0	Reanalyzed by: GSM2351204		GSM2353064	GSM2353065_A52084400939233091415421177246886.CEL	"SUBJ.1009, SLE, week16"	GSM2353065	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9890410958904	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1009	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.195	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353065/suppl/GSM2353065_A52084400939233091415421177246886.CEL.gz	0			GSM2353065	GSM2353066_A52084400939497101415421438760469.CEL	"SUBJ.1009, SLE, week52"	GSM2353066	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9890410958904	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1009	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.195	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353066/suppl/GSM2353066_A52084400939497101415421438760469.CEL.gz	0			GSM2353066	GSM2353067_A52084400940544091515421247226743.CEL	"SUBJ.0175, SLE, baseline"	GSM2353067	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.5506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0175	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.678	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353067/suppl/GSM2353067_A52084400940544091515421247226743.CEL.gz	0	Reanalyzed by: GSM2351007		GSM2353067	GSM2353068_A52084400940544091515421247226755.CEL	"SUBJ.0175, SLE, week16"	GSM2353068	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.5506849315068	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0175	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.678	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353068/suppl/GSM2353068_A52084400940544091515421247226755.CEL.gz	0			GSM2353068	GSM2353069_A52084400940548091515421247226932.CEL	"SUBJ.0175, SLE, week52"	GSM2353069	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.5506849315068	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0175	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.678	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.106	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353069/suppl/GSM2353069_A52084400940548091515421247226932.CEL.gz	0			GSM2353069	GSM2353070_A52084400939855091415421246947325.CEL	"SUBJ.0156, SLE, baseline"	GSM2353070	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7950819672131	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0156	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.872	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.174	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353070/suppl/GSM2353070_A52084400939855091415421246947325.CEL.gz	0	Reanalyzed by: GSM2352625		GSM2353070	GSM2353071_A52084400939855091415421246947346.CEL	"SUBJ.0156, SLE, week16"	GSM2353071	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7950819672131	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0156	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.872	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.174	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353071/suppl/GSM2353071_A52084400939855091415421246947346.CEL.gz	0			GSM2353071	GSM2353072_A52084400939855091415421246947319.CEL	"SUBJ.0156, SLE, week52"	GSM2353072	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7950819672131	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0156	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.872	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.174	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353072/suppl/GSM2353072_A52084400939855091415421246947319.CEL.gz	0			GSM2353072	GSM2353073_A52084400939232091415421177246841.CEL	"SUBJ.1321, SLE, baseline"	GSM2353073	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9342465753424	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1321	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353073/suppl/GSM2353073_A52084400939232091415421177246841.CEL.gz	0	Reanalyzed by: GSM2351038		GSM2353073	GSM2353074_A52084400940552091515421247348724.CEL	"SUBJ.1321, SLE, week16"	GSM2353074	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9342465753424	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1321	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353074/suppl/GSM2353074_A52084400940552091515421247348724.CEL.gz	0			GSM2353074	GSM2353075_A52084400940550091515421247348613.CEL	"SUBJ.1321, SLE, week52"	GSM2353075	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9342465753424	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1321	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353075/suppl/GSM2353075_A52084400940550091515421247348613.CEL.gz	0			GSM2353075	GSM2353076_A52084400939921091515421247126582.CEL	"SUBJ.1766, SLE, baseline"	GSM2353076	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 86.6967213114754	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1766	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.206	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353076/suppl/GSM2353076_A52084400939921091515421247126582.CEL.gz	0	Reanalyzed by: GSM2351755		GSM2353076	GSM2353077_A52084400939921091515421247126556.CEL	"SUBJ.1766, SLE, week16"	GSM2353077	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 86.6967213114754	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1766	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.206	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353077/suppl/GSM2353077_A52084400939921091515421247126556.CEL.gz	0			GSM2353077	GSM2353078_A52084400940545091515421247226808.CEL	"SUBJ.1766, SLE, week52"	GSM2353078	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 86.6967213114754	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1766	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.206	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353078/suppl/GSM2353078_A52084400940545091515421247226808.CEL.gz	0			GSM2353078	GSM2353079_A52084400940550091515421247348594.CEL	"SUBJ.0934, SLE, baseline"	GSM2353079	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6657534246575	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0934	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.35	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353079/suppl/GSM2353079_A52084400940550091515421247348594.CEL.gz	0	Reanalyzed by: GSM2351636		GSM2353079	GSM2353080_A52084400939234091415421177246986.CEL	"SUBJ.0934, SLE, week16"	GSM2353080	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6657534246575	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0934	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.35	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353080/suppl/GSM2353080_A52084400939234091415421177246986.CEL.gz	0			GSM2353080	GSM2353081_A52084400940549091515421247348537.CEL	"SUBJ.0934, SLE, week52"	GSM2353081	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.6657534246575	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0934	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.35	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353081/suppl/GSM2353081_A52084400940549091515421247348537.CEL.gz	0			GSM2353081	GSM2353082_A52084400939212081815420934610988.CEL	"SUBJ.0957, SLE, baseline"	GSM2353082	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8497267759562	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0957	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 93	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.868	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353082/suppl/GSM2353082_A52084400939212081815420934610988.CEL.gz	0	Reanalyzed by: GSM2352622		GSM2353082	GSM2353083_A52084400939272081315420891403952.CEL	"SUBJ.0957, SLE, week16"	GSM2353083	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8497267759562	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0957	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 93	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.868	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353083/suppl/GSM2353083_A52084400939272081315420891403952.CEL.gz	0			GSM2353083	GSM2353084_A52084400939272081315420891403947.CEL	"SUBJ.0957, SLE, week52"	GSM2353084	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8497267759562	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0957	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 93	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.868	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.151	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353084/suppl/GSM2353084_A52084400939272081315420891403947.CEL.gz	0			GSM2353084	GSM2353085_A52084400939113082215421026196571.CEL	"SUBJ.1374, SLE, baseline"	GSM2353085	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1374	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.242	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353085/suppl/GSM2353085_A52084400939113082215421026196571.CEL.gz	0	Reanalyzed by: GSM2352094		GSM2353085	GSM2353086_A52084400939115082215421026196709.CEL	"SUBJ.1374, SLE, week16"	GSM2353086	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5506849315068	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1374	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.242	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353086/suppl/GSM2353086_A52084400939115082215421026196709.CEL.gz	0			GSM2353086	GSM2353087_A52084400939113082215421026196544.CEL	"SUBJ.1374, SLE, week52"	GSM2353087	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.5506849315068	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1374	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.242	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353087/suppl/GSM2353087_A52084400939113082215421026196544.CEL.gz	0			GSM2353087	GSM2353088_A52084400940657100115421372840812.CEL	"SUBJ.0370, SLE, baseline"	GSM2353088	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.2602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0370	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353088/suppl/GSM2353088_A52084400940657100115421372840812.CEL.gz	0	Reanalyzed by: GSM2352363		GSM2353088	GSM2353089_A52084400940658100115421372840883.CEL	"SUBJ.0370, SLE, week16"	GSM2353089	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.2602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0370	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353089/suppl/GSM2353089_A52084400940658100115421372840883.CEL.gz	0			GSM2353089	GSM2353090_A52084400940659100115421372840965.CEL	"SUBJ.0370, SLE, week52"	GSM2353090	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.2602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0370	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353090/suppl/GSM2353090_A52084400940659100115421372840965.CEL.gz	0			GSM2353090	GSM2353091_A52084400939113082215421026196560.CEL	"SUBJ.0344, SLE, baseline"	GSM2353091	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.811475409836	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0344	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353091/suppl/GSM2353091_A52084400939113082215421026196560.CEL.gz	0	Reanalyzed by: GSM2352063		GSM2353091	GSM2353092_A52084400939113082215421026196557.CEL	"SUBJ.0344, SLE, week16"	GSM2353092	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.811475409836	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0344	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353092/suppl/GSM2353092_A52084400939113082215421026196557.CEL.gz	0			GSM2353092	GSM2353093_A52084400939113082215421026196556.CEL	"SUBJ.0344, SLE, week52"	GSM2353093	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 65.811475409836	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0344	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353093/suppl/GSM2353093_A52084400939113082215421026196556.CEL.gz	0			GSM2353093	GSM2353094_A52084400939269081315420891403760.CEL	"SUBJ.0725, SLE, baseline"	GSM2353094	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.0109589041095	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0725	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 176	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.956	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353094/suppl/GSM2353094_A52084400939269081315420891403760.CEL.gz	0	Reanalyzed by: GSM2352313		GSM2353094	GSM2353095_A52084400939269081315420891403765.CEL	"SUBJ.0725, SLE, week16"	GSM2353095	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.0109589041095	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0725	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 176	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.956	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353095/suppl/GSM2353095_A52084400939269081315420891403765.CEL.gz	0			GSM2353095	GSM2353096_A52084400939269081315420891403758.CEL	"SUBJ.0725, SLE, week52"	GSM2353096	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.0109589041095	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0725	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 176	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.956	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.099	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353096/suppl/GSM2353096_A52084400939269081315420891403758.CEL.gz	0			GSM2353096	GSM2353097_A52084400939235091415421177247074.CEL	"SUBJ.0009, SLE, baseline"	GSM2353097	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.0849315068493	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0009	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 106	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.971	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353097/suppl/GSM2353097_A52084400939235091415421177247074.CEL.gz	0	Reanalyzed by: GSM2351452		GSM2353097	GSM2353098_A52084400939234091415421177246957.CEL	"SUBJ.0009, SLE, week16"	GSM2353098	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.0849315068493	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0009	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 106	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.971	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353098/suppl/GSM2353098_A52084400939234091415421177246957.CEL.gz	0			GSM2353098	GSM2353099_A52084400939234091415421177246974.CEL	"SUBJ.0009, SLE, week52"	GSM2353099	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.0849315068493	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0009	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 106	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.971	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353099/suppl/GSM2353099_A52084400939234091415421177246974.CEL.gz	0			GSM2353099	GSM2353100_A52084400939272081315420891403949.CEL	"SUBJ.1377, SLE, baseline"	GSM2353100	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.9098360655737	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1377	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353100/suppl/GSM2353100_A52084400939272081315420891403949.CEL.gz	0	Reanalyzed by: GSM2351569		GSM2353100	GSM2353101_A52084400939269081315420891403788.CEL	"SUBJ.1377, SLE, week16"	GSM2353101	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.9098360655737	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1377	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353101/suppl/GSM2353101_A52084400939269081315420891403788.CEL.gz	0			GSM2353101	GSM2353102_A52084400939271081315420891403896.CEL	"SUBJ.1377, SLE, week52"	GSM2353102	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.9098360655737	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1377	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353102/suppl/GSM2353102_A52084400939271081315420891403896.CEL.gz	0			GSM2353102	GSM2353103_A52084400940070100715421373649396.CEL	"SUBJ.0661, SLE, baseline"	GSM2353103	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0661	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.079	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353103/suppl/GSM2353103_A52084400940070100715421373649396.CEL.gz	0	Reanalyzed by: GSM2351295		GSM2353103	GSM2353104_A52084400940067100715421373649248.CEL	"SUBJ.0661, SLE, week16"	GSM2353104	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8383561643835	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0661	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.079	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353104/suppl/GSM2353104_A52084400940067100715421373649248.CEL.gz	0			GSM2353104	GSM2353105_A52084400940069100715421373649377.CEL	"SUBJ.0661, SLE, week52"	GSM2353105	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.8383561643835	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0661	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 22	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.66	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.079	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353105/suppl/GSM2353105_A52084400940069100715421373649377.CEL.gz	0			GSM2353105	GSM2353106_A52084400940070100715421373649440.CEL	"SUBJ.1414, SLE, baseline"	GSM2353106	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.6219178082191	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1414	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.375	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353106/suppl/GSM2353106_A52084400940070100715421373649440.CEL.gz	0	Reanalyzed by: GSM2351737		GSM2353106	GSM2353107_A52084400940083100815421437950508.CEL	"SUBJ.1414, SLE, week16"	GSM2353107	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.6219178082191	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1414	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.375	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353107/suppl/GSM2353107_A52084400940083100815421437950508.CEL.gz	0			GSM2353107	GSM2353108_A52084400940080100815421437950354.CEL	"SUBJ.1414, SLE, week52"	GSM2353108	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.6219178082191	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1414	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.375	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353108/suppl/GSM2353108_A52084400940080100815421437950354.CEL.gz	0			GSM2353108	GSM2353109_A52084400939214081815420934611079.CEL	"SUBJ.0134, SLE, baseline"	GSM2353109	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.8465753424657	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0134	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.268	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353109/suppl/GSM2353109_A52084400939214081815420934611079.CEL.gz	0	Reanalyzed by: GSM2352232		GSM2353109	GSM2353110_A52084400939214081815420934611078.CEL	"SUBJ.0134, SLE, week16"	GSM2353110	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.8465753424657	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0134	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.268	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353110/suppl/GSM2353110_A52084400939214081815420934611078.CEL.gz	0			GSM2353110	